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1.0 Introduction 
The incidence rate of breast cancer has increased internationally and in Norway 
since the 1950s (1), and today breast cancer is the most frequent cancer diagnosis 
among women in Norway, with 2956 women diagnosed with the disease in 2012 (2). 
The five-year survival rate for women with breast cancer (all stages), increased from 
67 % in 1970 to 89 % in 2011 (3). The implication of both higher incidence and 
survival is that more women are living with the psychological and physiological 
symptoms that accompany the disease and its treatment. 
Women with breast cancer may have both subjective symptoms and 
objective signs of disease before they often receive multimodal treatment (4-7). 
Symptoms can be caused both by the illness itself and by treatment. Each treatment 
carries a risk of causing a set of new treatment-related symptoms (8-13). Symptoms 
represent a departure from the normal function or feeling (e.g., pain, nausea, or 
anxiety), are observed by the patient, and can seldom be measured directly. Self-
report is therefore most commonly used to register symptoms both in research and 
clinical situations.  
 Symptoms frequently reported for women receiving treatment for breast 
cancer are fatigue (8;14), arm morbidity (9), pain (15), nausea (13;16;17), difficulty 
sleeping (8;18), cognitive dysfunction (17;19) and depression (8).  Recent evidence 
shows that these women are experiencing multiple symptoms simultaneously (20-
22), which decreases the functional status and quality of life (QOL) for the women 
experiencing it. The evidence on multiple symptoms for this patient group is limited 
(20-22), despite extensive knowledge on individual symptoms. The symptom burden 
requires attention because it may affect the women and their families negatively. 
As a nurse, I was interested in investigating the symptom experience for 
women with breast cancer going through radiotherapy (RT), as nurses are typically 
confronted with symptoms that patients are experiencing through cancer treatment. 
When women with breast cancer start RT, they have already received one treatment 
(e.g., surgery) or a combination of treatments (e.g., surgery and chemotherapy 
(CTX)), which may lead to different symptoms. Additional RT is associated with 
further symptoms. These women usually receive RT as outpatients. Since these 
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patients are living at home, without being seen by health care providers every day, it 
is of great importance for these patients to be aware of the potential symptom 
burden and the trajectory of the symptoms that they may experience during 
treatment. Equally important for these patients is knowledge about strategies to 
help them cope better with the symptoms they experience. 
This dissertation examined the symptoms and QOL for 188 women with 
breast cancer before, during, and after RT. The study was part of a larger cohort 
study: “Advancing the science of symptom management and support for cancer 
patients and their caregivers”, which investigated symptoms and symptom clusters 
for patients and their family caregivers. Since the study was part of a larger cohort 
study, several decisions had already been made in respect to both study design and 
data collection. The “Theory of Unpleasant Symptoms” (TOUS) has been used when 
writing this dissertation, both as a helpful tool and framework in selecting variables 
for the analyses and in interpreting the complexity of symptoms (23). 
In summary, the main theme of this dissertation is the patient-reported 
outcomes for women with breast cancer before, during and after RT. The present 
study has investigated the high symptom burden for these women, how it changes 
over time, the various dimensions of the symptoms, what predicts the symptoms, 
and finally how the symptom burden affects QOL. 
 
1.1 Breast cancer – definitions and treatment 
1.1.1 Stage of disease 
Staging of breast cancer tumors is based on whether the cancer is invasive or non-
invasive and the size of the primary tumor (T), whether lymph nodes are involved 
(N), and whether the cancer has spread beyond the breast (M) (Table 1) (24). The 
TNM stages are then grouped into stages (Table 2). The stage of disease are used for 
understanding the prognosis of the patient, to guide treatment decisions, and to 
provide a common way to describe the extent of breast cancer, so that results can 
be compared and understood across countries. 
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Table 1 TNM Staging System for Breast Cancer 
 
 
Primary Tumor (T) 
TX    Primary tumor cannot be assessed 
T0    No evidence of primary tumor 
Tis     Carcinoma in situ 
T1     Tumor ≤ 20 mm in greatest dimension 
T2     Tumor >20 mm but ≤ 50 mm in greatest dimension 
T3     Tumor >50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall, 
and/or to the skin (ulceration or skin nodules)  
Note: Invasion of the dermis alone does not qualify as T4 
 
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed (e.g., previously 
removed) 
N0     No regional lymph node metastases 
N1  Metastases to movable ipsilateral level I, II axillary lymph 
node(s) 
N2  Metastases in ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected * ipsilateral 
internal mammary nodes in the absence of clinically evident 
axillary lymph node metastases 
N3     Metastases in ipsilateral infraclavicular (level III axillary) 
Lymph - node(s) with or without level I, II axillary lymph node 
involvement; or in clinically detected *ipsilateral internal 
mammary lymph node(s) with clinically evident level I, II 
axillary lymph node metastases; or metastases in ipsilateral 
supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement 
 
Distant Metastases (M) 
M0     No clinical or radiographic evidence of distant metastases 
M1  Distant detectable metastases as determined by classic clinical 
and radiographic means and/or histologically proven larger 
than 0.2 mm 
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Table 2  TNM Staging Grouping for Breast Cancer 
 
Staging Grouping 
0  Tis  N0  M0 
I  T1*  N0  M0 
IIA  T0 – T1* N1  M0 
T2  N0  M0 
IIB  T2  N1  M0 
T3  N0  M0 
IIIA  T0 – T2  N2  M0 
T3  N1 - N2  M0 
IIIB  T4  N0 – N3  M0 
IIIC  Any T  N3  M0 
IV  Any T  Any N  M1 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh 
Edition (2010) published by Springer Science and Business Media LLC, www.springer.com. 
*T1 includes T1 mic. 
 
Breast cancer can occur bilaterally, most commonly in patients with infiltrating 
lobular carcinoma (25;26). The incidence of primary breast cancer in the 
contralateral breast or synchronous bilateral breast cancer is low, but has a negative 
impact on the prognosis (25;26). 
 
1.1.2 Treatment 
National guidelines for the treatment of breast cancer have existed in Norway since 
1981, aimed at ensuring uniform cancer treatment of high quality for the patient 
group (27). In localized breast cancer, the goal is always curative, while with 
metastatic (distant) disease there is no curative option. The treatment is influenced 
by clinical characteristics (age, menopausal status, stage of disease) and pathology 
features. Treatment is commonly multimodal, with combinations of surgery, RT, CTX, 
hormones and antibody therapy (4-7). In the guidelines, a strict flow diagram 
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describes the standard choice of treatment in the multiple different patient 
subgroups. 
 
1.1.3 Surgery 
The goal of surgery is to achieve local control, before metastasis occurs. Surgical 
options are breast – conserving surgery (BCS) or mastectomy. The decision on 
mastectomy is influenced by both medical and psychological factors, and more 
women seem to choose mastectomy when reconstruction is conducted during the 
same procedure (28;29). 
Sentinel lymph node biopsy (SLNB) is the initial standard axillary lymph node staging 
procedure for women with invasive breast cancer. In the case of large tumors or 
known metastases to lymph nodes, a routine axillary lymph node dissection (ALND) 
is performed without previous SLNB. In ALND, a minimum of 10 lymph nodes are 
removed, most often at the same time as BCS or mastectomy (27;28;30).  
 
1.1.4 Radiotherapy 
RT is given postoperatively after BCS. The main goal is to reduce the risk of local or 
distant relapse, and thereby to increase survival (6;7). The most common site of 
recurrence after BCS is the conserved breast, and post-operative RT is therefore 
recommended for the whole breast. RT is recommended after mastectomy if 
microscopic resection margins are positive (with tumor cells) or uncertain. 
Furthermore, RT is recommended for patients with metastases of at least 2mm in an 
axillary lymph node, breast cancer stage III, or occasionally without previous surgery 
in patients with very large tumors or inflammatory breast cancer (6;7;27).   
 
1.1.5  Chemotherapy 
Several CTX regimens are used. Combining cytostatic drugs (polychemotherapy) has 
proved more effective than using one drug alone (27;31-33). The choice of CTX 
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regimen for each patient depends on a number of complex clinical considerations 
(age, menopausal status, HER2 status, proliferation status (Ki67)) (27;31;34). 
 
1.1.6 Hormonal and antibody therapy 
In patients with estrogen- and/or progesterone-receptor-positive tumors, hormonal 
treatment has considerable effects on survival (32;33). Hormonal therapies affect 
hormone-receptor-positive breast cancer in two ways: by lowering the amount of 
estrogen in the body, or by blocking the action of estrogen breast cancer cells. Types 
of hormonal therapies include aromatase inhibitors, selective estrogen receptors, 
and estrogen receptor down regulators (27;31;33). 
Antibody therapy/immunotherapy is given to patients with specific 
characteristics of the cancer cells, such as a protein that causes cancer cells to grow 
in a rapid and abnormal way (HER2-positive) (27;31;32). 
 
1.2 Background 
1.2.1 Literature Search 
Systematic searches were conducted, based on two main topics with the following 
search terms: 
1. Symptoms – breast cancer – radiotherapy 
2. Quality of life (QOL) – breast cancer – radiotherapy 
 
For all searches, the following multiple relevant multidisciplinary electronic 
databases were used:  MEDLINE/Ovid, PsychINFO/Ovid, CINAHL.  Every term was 
searched for using both the thesaurus of the databases and the free text/key word 
method. In addition, manual searches of reference lists were an important 
contribution to retrieving all available and relevant literature. The literature searches 
were conducted in collaboration with a medical librarian. 
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1.2.1 Symptoms – definitions 
Symptoms are defined as “the perceived indicators of change in normal functioning 
as experienced by patients” (Rhodes and Watson, 1987, p. 242) (35). The definition is 
based on a subjective measurement, and it implies that the symptom can only truly 
be known and described by the person experiencing it. Therefore, symptoms should 
be reported by the individuals who experience the symptoms themselves.  
Each specific symptom has several measurable dimensions (e.g., 
frequency/timing, severity/intensity, distress). These different dimensions are 
referred to as the multiple dimensions of a symptom, and are described to add 
valuable information about the symptom experience, in contrast to only reporting its 
occurrence (23;36) 
Recent evidence suggests that women who receive treatment for breast 
cancer experience multiple symptoms, rather than individual symptoms (20-22). 
Each of the different treatments represents a risk of several treatment-related 
symptoms.  
After surgery, the women most commonly describe symptoms such as pain, 
lymphedema and fatigue (9;11). CTX in these patients is associated with a number of 
symptoms, often occurring simultaneously. Fatigue is the most commonly reported 
symptom(8;16;17;37). Nausea, hair loss, a sore mouth, taste and appetite change, 
diarrhea, and constipation are other commonly reported symptoms for women 
receiving CTX for breast cancer (13;16;38-40). RT is associated with additional 
symptoms (e.g., fatigue, swelling of breast and pain) for women with breast cancer 
while menopausal symptoms such as hot flashes, difficulty sleeping, and fatigue are 
commonly described by women receiving hormones (39;41-45).  
The conceptualizations of multiple symptoms that occur concurrently have 
been given considerable attention in the symptom literature for cancer patients in 
general and for patients with breast cancer in particular.  A ‘symptom cluster’ is 
defined as three or more concurrent symptoms that are related to each other (46). 
Investigating symptom clusters in a variety of different cancer diagnoses (i.e., breast, 
ovarian, head and neck, and colorectal cancer) was one of the main aims for the 
larger cohort study that this dissertation is based on. This dissertation is not focused 
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on symptom clusters, but on multiple symptoms that women experience before, 
during and after RT for breast cancer. A set of multiple symptoms may differ from a 
symptom cluster, by including symptoms that occur simultaneously, while the 
symptoms within a symptom cluster must be related to each other, sharing the same 
etiology. The focus of the dissertation was the symptom burden of multiple 
symptoms experienced by patients in relation to RT. 
 
1.2.2 Symptoms – literature review 
Early in the research process, a gap in the literature describing multiple symptoms 
for women who are receiving RT for breast cancer was detected. The majority of 
papers focused on individual symptoms (e.g., fatigue, nausea, or pain), even though 
women with breast cancer more commonly suffer from multiple symptoms (20-22). 
In addition, most literature was found to investigate only single dimensions of a 
symptom (e.g., distress or frequency) in contrast to investigating the various 
dimensions of the symptom (e.g., frequency, severity, and distress). The vast 
majority of the literature described symptoms for this patient group post treatment 
and not during treatment. Finally, few studies were found to investigate symptoms 
longitudinally during the course of RT. A summary of the literature is presented 
below. 
 
Longitudinal studies of multiple symptoms  
Only four prospective longitudinal studies investigated symptoms longitudinally for 
women with breast cancer during RT (10;40;45;47), and three different symptom 
inventories were used to measure symptoms.  
For three of the studies (10;40;45) an increase in symptom experience and 
symptom severity during the course of RT was found. Wengstrom et al. (2000), who 
investigated symptoms, side effects and QOL for women with breast cancer (n = 134) 
during and following RT, found an increase in symptoms and their severity during 
treatment (40). This finding has been supported in more recent studies (10;45). 
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Further, the study by Wengstrom et al. found that symptoms slowly decreased to 
pre-treatment levels within three months after the last RT session (40). Similar 
findings were made in a convenience sample of 30 women with breast cancer 
conducted by Knobf et al. (10), who also found an improvement within three months 
after last RT. In contrast, a study investigating the occurrence and burden of side 
effects during and after RT for breast cancer (n = 171) found that the total burden of 
side effects remained higher six months after the last RT sessions (45).  
In a retrospective study, Warmer et al. (47) investigated multiple symptoms 
two weeks, three months and 12 months after treatment of early breast cancer (n = 
329). They found that the addition of RT and/or CTX to surgery made little difference 
to symptoms reported (47). 
In summary, the literature describing multiple symptoms longitudinally 
during RT is scarce, and highlights the need for additional research. 
 
Multiple symptoms in heterogeneous cancer samples  
Seven more studies (48-54) investigated symptoms for women with breast cancer as 
part of a heterogeneous sample. Portenoy et al. (48) investigated symptom 
prevalence, characteristics and distress in a heterogeneous sample of cancer 
patients (n = 243), including women with breast cancer (n = 70). In the latter study, 
the number of symptoms was found to be strongly associated with heightened 
psychological distress and poorer QOL. However, the study was of cross-sectional 
design, and almost two-thirds of the sample had metastatic disease. 
Munro and Potter (49) investigated distress caused by symptoms after radical 
RT in a heterogeneous sample of cancer patients (n = 110), including 72 patients with 
breast cancer. The study found that the most frequent symptoms did not necessarily 
cause the most distress. For women with breast cancer, significant changes were 
found in symptoms during the course of RT. Tiredness was found to increase 
between weeks two and three of the treatment, and returned to pre-treatment level 
at the first follow-up visit (week 7 after pre-treatment data). The distress related to 
certain symptoms (numbness, worry about effects of the disease and treatment on 
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family members, and feeling anxious) decreased between the initial assessment and 
the follow-up. 
Several of the papers (50-54) described validation of a symptom inventory 
in different languages, all using cross-sectional design. Women with breast cancer 
represented from 10 % to 36 % of the samples, and fatigue was rated as the most 
severe symptom in all the studies. 
In summary, the literature describing multiple symptoms in women with 
breast cancer includes studies with both cross-sectional and longitudinal design, the 
use of several different symptom inventories, and variations in study samples, which 
makes it difficult to summarize the results.  
 
1.2.3 Quality of life – definitions 
There is not one universally agreed definition of QOL, and clear definitions are not 
often presented in publications. QOL could be defined as “a person’s sense of well-
being that stems from satisfaction or dissatisfaction with areas of life that are 
important to him/her” (Ferrans 1990, page 249) (55). The definition is based on a 
subjective measurement, and implies that QOL can only truly be known and 
described by the person experiencing it, and should therefore be self-reported. 
In health science, QOL is regarded as a multidimensional concept that 
includes several areas of life affected by disease and treatment. A health-related 
QOL inventory may include some or all of the following dimensions: 
psychological/emotional functioning, physical functioning, social functioning, disease 
specific symptoms/pain, vitality, social functioning, treatment-related side-effects, 
and spiritual aspects (56-58). QOL inventories can either be generic or specific to a 
disease. A disease-specific questionnaire will include disease- and treatment-specific 
characteristics, and can therefore not be used for other populations. A generic QOL 
inventory does not include disease-specific questions, and can therefore be used and 
compared across populations.  
Health Related Quality of Life and QOL are used interchangeably in the 
cancer and symptom literature. In the current dissertation, QOL refers to both terms. 
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1.2.4 Quality of life – literature review 
The number of research papers on women with breast cancer and QOL is substantial. 
However, the literature describing QOL in relation to RT in this patient group is more 
limited, with 12 identified studies (40;59-69). Single symptoms (e.g., pain, fatigue, 
nausea) and their effect on QOL have been well studied. However, this is not part of 
the scientific background for the current study, where the effect of multiple 
symptoms was the scope of interest. Different factors (e.g., demographic, clinical, 
and treatment) that influence QOL for women receiving RT for breast cancer have 
been described in some studies (66-69), as well as the effect of multiple symptoms 
(40;59;62;64;65) on QOL. A review of the literature is presented below. 
 
Radiotherapy has minimal effect on quality of life for women with breast cancer 
Four studies (59-62) found that RT had a minimal effect on QOL during or shortly 
after the course of RT. 
In one study (n = 175), no negative effects on QOL from baseline (start of RT) 
to six weeks after commencing RT were found (60). Similarly, in another study by Lee 
et al. (2008) (n = 61), QOL was assessed at baseline, at the end of RT, and seven 
months after the completion of RT (59); no changes in QOL were found. Fatigue and 
breast symptoms increased during RT, but returned to baseline levels after seven 
months. However, fatigue was found to be the strongest predictor for poorer QOL 
after RT in this study (59). 
Reidunsdatter et al. (62) investigated early effects of RT on QOL and explored 
treatment-related contributors to the development of fatigue during RT (n = 248). 
Data were collected before the start of RT (baseline) and immediately after the end 
of RT. RT had limited effect on QOL, but breast symptoms and fatigue increased 
significantly during RT, as in the study by Lee et al. (59). 
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Radiotherapy has effect on quality of life for women with breast cancer 
Other studies (40;61;63-65) investigating QOL during and after the course of RT 
found a change in QOL during the course of RT. A study conducted by Whelan et al. 
(2000), using data from a clinical trial running between 1984 and 1989 (n = 416), 
evaluated the effect of RT on QOL, by comparing the treatment group (RT) with a 
control group that did not receive RT after undergoing lumpectomy and ALND. QOL 
was measured at the start of treatment, as well as one month and two months 
thereafter. RT had a negative effect on QOL during treatment; however the RT 
regimen used in this study is no longer commonly used (63). Wengstrom et al (2000) 
conducted a study where the purpose was to describe symptoms, side effects and 
QOL of women with breast cancer (n = 134) during and following RT (40). In this 
study, QOL was found to be poorest at baseline before treatment had started, and 
an improvement was seen after the completion of treatment. As in the other studies 
an increase in symptoms and their severity as the treatment progressed was found 
(40). 
Browall et al. (64) found a decreasing tendency in QOL during the course of 
RT for women with breast cancer (n = 150) (64). The general finding from the latter 
study was that adjuvant treatment was associated with decrease in overall QOL, 
physical and role functioning, and body image, and an increase in anxiety as well as 
in several other symptoms. Budischewski et al. conducted a study where the aim was 
to evaluate for changes in QOL during the course of RT, with a focus on subgroup 
analyses of patients with unchanged, increased or decreased QOL (65). The sample 
consisted of 61 women with breast cancer receiving RT for breast cancer, and QOL 
was measured three times: at the beginning of RT, in the fourth week and six weeks 
after the end of treatment. The interpretation of these data is difficult, due to the 
small sample size, but 15 patients described a decrease in QOL, while 25 and 21 
patients described increased or no changes in QOL, respectively. 
Finally, a study conducted by Deshields et al (2005), investigating the course 
of emotional adjustment and QOL among breast cancer survivors (n = 94) 
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immediately following RT, found that participants reported elevated levels of 
depression, low levels of anxiety and diminished QOL at the end of treatment. 
However, both QOL and depression improved significantly within two weeks after 
treatment, before they stabilized (61). 
 
Predictors of quality of life among women with breast cancer receiving 
radiotherapy 
Four studies investigated predictors of QOL during RT (66-69). In a longitudinal study 
of women with breast cancer after BCT during and after RT (n = 109), QOL was 
assessed at the beginning, at the end, and six weeks after RT (66). The findings from 
this study revealed that CTX significantly lowered QOL compared to hormonal 
therapy or RT alone. Another study conducted by Hopwood et al. (2007) investigated 
the impact of age and other cancer treatments on QOL for women receiving RT for 
breast cancer (n = 2208) (67). This study found CTX together with age to be a risk 
factor for poorer QOL for women about to start RT (67). In a study including 1057 
newly diagnosed patients with either breast cancer (n = 627) or prostate cancer (n = 
430), RT was not a significant predictor of diminished QOL (68). In the same study, 
women who received CTX and had played a more passive role in the treatment 
decision-making were found to have significantly greater distress and lower QOL at 
12 weeks consultation after treatment consultation. 
Another study by Munshi et al. (2010) compared QOL in women with breast 
cancer (n = 113) treated with mastectomy and RT versus BCS and RT (69), at baseline 
(pre-RT), midway in RT, and at the end of RT. The study found no significant 
differences in QOL between the mastectomy and the BCS group, and no significant 
change in QOL after RT in both groups (69). 
It is difficult to summarize the results from previous publications on QOL for 
women receiving RT for breast cancer, as the studies vary in design, sample sizes, 
and QOL inventories, and show conflicting results. It seems that RT in itself has 
limited effect on QOL, but the results have been conflicting. 
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1.3 Theoretical framework – the Theory of Unpleasant Symptoms 
For the larger cohort study, of which this study is a part, the Theory of Symptom 
Management (70) served as the theoretical framework, and was also used in the first 
publication of this dissertation However, the theoretical framework used for this 
study is the theory of unpleasant symptoms (TOUS) by Lenz and Pugh (1997) which 
was found to be more appropriate for the present study, as it captures several 
aspects of the symptom experience that were investigated in the present study (23). 
Based on the paper by Lenz and Pugh (1997) the TOUS will be presented below (23). 
The purpose of the theory is to improve understanding of symptom 
experience in various clinical situations, and in turn to diminish negative effects of 
the symptoms experienced.  
The theory was first designed to integrate existing knowledge about different 
symptoms, with the premise that there are similarities across different symptoms, 
and it provides common definitions and dimensions for examining symptoms. The 
TOUS was first published in Advances in Nursing Science in 1995 (71). A revised 
version (23) emphasizes that symptoms can either occur alone, or in combination 
with other symptoms (multiple symptoms) (Figure 1). Further, the TOUS describes 
that multiple symptoms can either occur as a result of a single event (e.g., 
physiological factors such as CTX), or that one symptom can lead to another 
symptom (e.g., anxiety may result in sleep disorders), (Figure 1). The theory consists 
of three major concepts; the symptom, influencing factors and performance 
outcomes (Figure 1).  
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Figure 1 The Theory of Unpleasant Symptoms (TOUS)  
 
Reprinted with permission from Advances in Nursing Science, Issue: Volume 19(3), March 
1997, pp 14-27, Copyright©1997 by Aspen Publisher, Inc. 
 
The theory describes the symptoms to vary in intensity, degree of distress, 
timing and quality. The intensity dimension can also be described as the severity or 
the strength of the symptom. Intensity is described to be the simplest aspect of the 
symptoms to rate according to the TOUS, and is frequently used in clinical situations 
(e.g., pain on a scale from 0-10). The time dimension includes the way symptoms 
vary in duration and frequency. Duration describes the length of time the symptom 
continues, and also how often it occurs. It is common to differentiate acute from 
chronic symptoms, and they are often also treated differently. According to the 
model, the distress dimension reflects to which degree an individual are bothered by 
the symptom, and further refers to the meaning that the individual gives the 
symptom. The final dimension of the symptom described in the TOUS is quality. By 
including this dimension the theory includes a personal aspect in the description of 
symptoms, as the different symptoms will be described differently for the various 
symptoms (e.g., sticking for pain). This aspect will need a qualitative approach, if 
captured in research, and the patients must be able to describe the experience of 
the symptom.  
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The influencing factors of the symptoms (Figure 1), are identified by Lenz & 
Pugh to be physiological factors, psychological factors, and situational factors. The 
physiological factors involve anatomical, physiological, genetic, and treatment-
related variables, and are described to influence the occurrence of symptoms and 
how it is experienced. In the present study several of the physiological factors (stage 
of disease, comorbidities, treatment variables, and age) were investigated as 
predictors of the symptoms and its trajectory using regression models. Psychological 
factors are described as one of the more complex components of the model, and 
include both affective and cognitive variables. These factors will possibly affect the 
individual response to the symptom and could possibly intensify it (e.g., anxiety, 
anger, depression). Situational factors cover the individuals’ environment, both 
social and physical. Examples of situational factors are marital status, socioeconomic 
status, lifestyle behaviours (exercise, smoking, alcohol consumption), and social 
support. The physical environment (humidity, pollution, noise etc.) is also described 
to influence the experience of symptoms in the TOUS. Several of the social factors of 
the patients’ lives have been investigated (marital status, education, employment 
status) in the present study. All of the three influencing factors may interact with 
each other, as well as they influence the symptom experience. 
Lenz and Pugh have defined the outcome of the above concepts as 
performance (Figure 1), and is described as the consequences of the symptom 
experience. A symptom or set of symptoms may give a number of different 
performance outcomes (e.g., physical impairment, changes in work situation, QOL), 
and is based on the assumption that the experience of symptoms can have an 
impact on a person’s ability to function. The performance status is described to 
possible have a feedback effect on both the situational factors and directly at the 
symptoms by the model. 
In the present study, the influencing factors, the various dimensions and the 
performance outcome of the symptoms has been investigated. 
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2.0 Aims of the study  
The main aim of this study was to investigate the various dimensions of multiple 
symptoms and QOL for women receiving RT for breast cancer. 
More specific, the following research questions have been explored in the 
dissertation; 
 
1. Describe the differences in symptom occurrence, frequency and distress for 
 women with breast cancer who have undergone surgery, based on whether 
 they have received CTX or not (Paper I) 
2. Investigate predictors for total number of symptoms for women who have 
had surgery for breast cancer (Paper I) 
3. Describe QOL before start of RT based on whether they have received CTX or 
not (Paper I) 
4. Investigate changes over time in occurrence, severity, and distress of 
common symptoms during and after RT for breast cancer patients (Paper II) 
5. Evaluate predictors for the various dimensions (occurrence, severity, distress) 
of common symptoms during and after RT for breast cancer patients (Paper 
II) 
6. Evaluate predictors of change over time for the various dimensions 
(occurrence, severity, distress) of common symptoms during and after RT for 
breast cancer patients (Paper II) 
7. Evaluate predictors for the level of QOL through the course of RT for women 
 with breast cancer after surgery (Paper III) 
8. Evaluate predictors of change in QOL through the course of RT for women 
with breast cancer after surgery (Paper III) 
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3.0 Methods  
3.1 Study design 
This longitudinal descriptive study is part of a larger cohort study investigating 
symptoms and symptom clusters in oncology patients and their family caregivers. 
The main study collected data on four different cancer diagnoses (i.e., colon-, 
ovarian-, head and neck-, and breast cancer) and their caregivers, and had a six 
months follow-up. Clinical and QOL data were collected at five (breast and head and 
neck cancer) or eight (colon- and ovarian cancer) time points for patients, and at 
three time points for the caregivers. In addition, blood samples were taken for 
genetic analyses to be used in the main study. The timing for data collecting was 
chosen in order to be able to capture the expected maximum increase in symptom 
burden after treatment. 
Breast cancer patients were recruited at the RT department, Oslo University 
Hospital, Norwegian Radium Hospital from December 2008 until June 2009.  
 
3.2 Patient recruitment 
A team consisting of three study nurses and the PhD student recruited patients to 
the study. The patients were first introduced to the study by one of the clinical 
nurses at the RT outpatient clinic eight days prior to the start of RT. These nurses 
were trained in approaching the patients, giving all patients similar information. 
Potential study participants were then introduced to one of the members of the 
recruitment team. When patients agreed upon being approached, they were given 
both written and oral information about the study. After signing the consent form, 
they were enrolled into the study, and given a study identity number. A valid 
baseline measurement was compulsory, and all patients, who signed the consent 
form but did not fill out the questionnaires within four weeks, were excluded from 
the study.  
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3.3 Inclusion and exclusion criteria 
Patients were invited to participate if they were adults (≥ 18 years of age); able to 
read, write and understand Norwegian; and scheduled to receive RT for breast 
cancer or ductal carcinoma in situ (DCIS). Patients were excluded if they were to 
receive RT to the brain or had a disease that affected their cognitive ability and if 
they did not fill in the baseline questionnaire. 
 
3.4 Data collection and follow-up 
When the consent form was signed, each patient received the first package of 10 
questionnaires. Five of the questionnaires were used for this dissertation, and will be 
presented below (chapter 3.6). At the predefined time points, new questionnaires 
were sent home to the participants by post. If patients did not fill out the 
questionnaires, one reminder was sent out by post for each time point.  
Baseline (Time 1) in the present study was approximately one week prior to 
the start of RT. The first follow-up (Time 2) was one month after baseline, and the 
next assessment (Time 3) was after one additional month. Assessment points four 
(Time 4) and five (Time 5) were three and six months after baseline respectively, and 
were intended to capture the longitudinal perspective of the RT. 
Age, stage of disease, treatment goal (curative/palliative), treatment status 
(i.e., primary treatment, recurrence, progression), and types of previous treatments 
were obtained by the research team from the medical record and documented in 
case report forms (CRFs). Different nurses and doctors, often at the local hospitals, 
filled out the CRFs for clinical data six months after inclusion. In order to obtain 
consistency in the data collection, there was a guide on how to fill out CRFs, both at 
baseline and at six months after baseline. Previous cancer treatments were 
categorized as surgery (i.e., mastectomy, BCS, ALND, SNLB, other), CTX, RT, 
hormonal therapy, immunotherapy, or other. Information on distant metastases was 
also collected (i.e., lymph nodes, skeleton, brain, liver, lung, peritoneum, other). In 
the CRF after six months, information on recurrence (yes/no), total dose and number 
of fractions of RT, as well as area of RT were collected. Information on other 
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treatments over the six-month follow-up periods was also reported (i.e., CTX, 
hormonal therapy, immunotherapy, surgery). Finally, data on disease status (i.e., 
alive-tumor free, alive-tumor free after treatment for recurrence, alive-stable 
disease, alive-progression, never tumor free after treatment for primary cancer or 
recurrent disease) and death (i.e., death-index tumor, death-other disease with 
active tumor, death-other disease and tumor free, death-unknown) were collected. 
 
3.5 Data handling and initial quality assurance 
The questionnaires and CRFs were electronically scanned by a research facility office, 
Kontor for Klinisk Forskning (KKF) at the Norwegian Radium Hospital. The routines 
for scanning were discussed with the staff, in order to maintain high compliance in 
all steps of the research process. When boxes within the questionnaires had been 
left open, if an X or tick was placed between two boxes, or if several boxes were 
ticked in one line, the machine stopped and the data was manually checked. Both 
empty boxes and X’s between two boxes were registered as missing items. If 
patients ticked several boxes for education, the box for the highest level of 
education was used. The machine also stopped if there was additional writing; this 
had to be typed in manually. All the data entry and CRFs were double-checked by the 
staff at KKF. When all data files were complete, an additional quality assurance was 
initially performed by checking 10 % of the charts against the paper version of both 
the CRFs and the questionnaires. Due to the level of errors detected, all 188 cases at 
all five time points and all CRFs were double-checked manually against the paper 
versions, and corrected when needed. 
 
3.6 Instruments 
Patients were asked to fill out a package of 10 questionnaires (a demographic 
questionnaire, comorbidity score, performance status, symptom inventory, pain 
inventory, two QOL measures, sleep disorder, depression scale, and fatigue scale). 
For this dissertation, results from five of the questionnaires (demographic 
  27  
questionnaire, comorbidity score, performance status, symptom inventory, and one 
QOL inventory) were used to answer the research questions in the present study, 
and are presented below. 
A pilot study was conducted before the data collection started. The purpose 
of the pilot study was three fold: 1) to find out how much time the patients used to 
fill out the whole package of 10 questionnaires, 2) to test the logistics in the data 
collection process, and 3) to get feedback on a questionnaire we had translated into 
Norwegian (see 3.6.4). More details on the translation process will be given below. 
Ten patients with cancer (i.e., ovarian, colon rectal, breast, head and neck cancer, 
and lymphoma), comprising six women and four men, were recruited to the pilot 
study. The patients took between 8 and 35 minutes to fill out the 10 questionnaires. 
 
3.6.1 Demographics 
Patients provided information on marital status (married, partnered or 
unmarried/divorced/widowed), living situation (living alone or with someone, 
including children), level of education (primary, secondary, college/university), and 
employment status (full/part time, sick-leave/disability benefit, retired/other). 
Only baseline data on the demographic variables have been used in the present 
study. 
 
3.6.2 Karnofsky Performance Status Scale (KPS) 
Physical functioning was assessed by self-report, using the KPS. This scale is 
extensively used to evaluate the performance status of an individual cancer patient 
both in clinical practice and in research. The KPS has a well-established construct 
validity and reliability and it is considered a global indicator for functional status in 
cancer patients (72-74). The Norwegian version has been used in several Norwegian 
studies of cancer patients (75-77). The KPS score ranges from 0 (death) to 100 (the 
individual is able to carry on normal activities). As patients in this study were 
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outpatients, the range of the scale from 40 (disabled and need of special care) to 100 
was used. The patients were asked to fill out the KPS at all five time points. 
 
3.6.3 Self-Administered Comorbidity Questionnaire (SCQ – 19) 
Information on comorbidities was obtained through self-report using the SCQ-19 
(78). The number of, treatments for, and functional impact of health problems were 
evaluated by listing 16 common comorbidities and three optional conditions. Patients 
were asked to indicate whether they had the co-morbid condition (yes/no); if they 
had the condition, they were asked if they were receiving treatment for it (yes/no); 
and finally, if it limited their activities (yes/no). The total SCQ-19 score range from 0 
to 57 when the three optional items are used (78). A higher total score indicates a 
more severe co-morbidity profile. The SCQ has established validity and reliability for 
the assessment of comorbidities in patients with chronic medical conditions (78) and 
has been used in previous studies in Norway (75;79). 
Patients were coded as having the co-morbid condition if any of the three 
boxes were checked (i.e., if they had the condition, if they received treatment for it, 
or if it limited their activities), even if the patient had checked ‘no’ on ‘do you have 
the comorbid condition’. A sum score of the SCQ was used in the present study. The 
patients were asked to fill out the SCQ at baseline, and at three and six months after 
baseline, and data from all time points have been used in the present study. 
 
3.6.4 Memorial Symptom Assessment Scale (MSAS) 
The MSAS was used to obtain data on the patients’ symptoms, and is one of the 
important outcome measures in the study, together with QOL. The MSAS contains a 
list of 32 physical and psychological symptoms (36). For each symptom, patients are 
asked to indicate whether or not they had the symptom during the past week (i.e., 
occurrence). If they have experienced the symptom, they are asked to rate its 
frequency (not used in our analyses), severity, and distress. Severity is rated using a 
four - point Likert Scale (i.e., 1 = slight, 2 = moderate, 3 = severe, 4 = very severe), 
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while symptom distress is rated using a five-point Likert scale (i.e., 0 = not at all, 1 = 
mild, 2 = moderate, 3 = severe, 4 = very severe).  
The MSAS has three valid subscales (i.e., Global Distress-Index, a 
psychological symptoms subscale (PSYCH), and a physical subscale) (36).  
The reliability and validity of the instrument is well described in Portenoy’s 
original work (36), and the instrument has been extensively used internationally 
(48;80-86). 
In the analysis of these data, patients were coded as having the symptom if 
one or more of the boxes were checked (i.e., frequency, severity, or distress) even if 
the patient had checked “do not have” the symptom. We followed the same 
procedures as done in other studies (87;88). Missing items were coded as the patient 
did not have the symptom. The present study did not use any of the three valid 
subscales developed for the instrument, as we were interested in the frequency and 
mean scores of occurrence, severity, and distress, of the reported symptoms. 
In the present study the occurrence rate (i.e., total number of symptoms) as 
well as the mean severity and distress scores have been reported and used in the 
regression analyses. The patients were asked to fill out the MSAS five times, and all 
five time points have been used in the present study. 
 
3.6.5 Translating the MSAS into Norwegian 
The MSAS was translated into a Norwegian version using a standard forward–
backward translation, based on MAPI Institute guidelines (89), after receiving 
permission from the developer of the instrument (Dr. Portenoy). Four bilingual 
health care providers individually translated the English version into Norwegian. 
After the translations, all four met for discussion and transformation of the four 
versions into one. Minor disagreements were resolved through discussion. The 
unified Norwegian version was then sent to a professional translator for a back 
translation into English. The back-translated English version was sent to the 
developer of the instrument, asking for comments. The next step in the process was 
to pilot test the Norwegian version of the MSAS, as described above. The patients 
did not comment on or have any questions regarding the questionnaire (MSAS). 
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Unfortunately, the Norwegian version contained a column asking the patients to rate 
the frequency of the last eight symptoms in the questionnaire, while the original 
version did not. The issue has been discussed with Dr. Portenoy, and the instrument 
was used without removing the frequency dimension.  
Formal psychometric testing was not performed for the translated version, as 
the population in the present study (i.e., patients with breast cancer) was part of the 
population in the original paper (i.e., patients with colon, prostate, breast, or ovarian 
cancer) conducted by Portenoy et al. (36). 
 
3.6.6 Short Form 12 (SF – 12) 
QOL was measured using the SF-12 (Version 1) (56), which is a generic QOL measure. 
It was developed to provide a shorter, yet valid alternative to the frequently used 
MOS 36-item short form health surveys (SF-36) (90). The SF-12 contains a subset of 
12 items from the SF-36, including one or two items from each of the eight subscales 
(e.g., physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional, mental health). Information from the 12 items is used to 
construct physical and mental component scores (PCS and MCS) (91). The scoring 
scheme for SF-12 (V1) does not allow any missing data in the 12 items. The sum score 
is calculated only if all 12 items have valid responses. The SF-12 PCS and MCS 
summary measures are scored using norm-based methods from the 1998 general 
United States (U.S.) population, with a mean of 50 and a SD of 10. The implication is 
that scores above or below 50 are interpreted as being above or below the mean 
scores in the general U.S. population (91;92). The advantage of the standardization 
and norm-based scoring of the PCS and MCS is that results for one summary score 
can be compared with results for the other and the scores have a direct 
interpretation in relation to the distribution of scores in the general U.S. population. 
These scores are similar to cut- off scores for the Norwegian general population (i.e., 
mean PCS 50.3, SD 8.8 and mean MCS 50.6, SD 9.9) (57). Higher PCS and MCS scores 
indicate better QOL.  There is no general consensus on the minimum clinical 
significant change in the SF-12 (93). 
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The SF-12 has undergone extensive validity and reliability testing through 
cross-validation of item selection and scoring in nine countries (57) and has been 
widely used for cancer patients (87;94;95). The Norwegian version is the result of a 
comprehensive translation of the original, and has satisfactory validity and reliability 
in Norwegian cancer patients (57;93). We did not perform reliability testing for the 
specific study sample. Cronbach’s alpha is not really appropriate for the two-
component scores of the SF-12 (V1), because the two-component scores are based 
on different weights and factor analysis loadings, and they are not the same for 
every item (91).  
The patients were asked to fill out the SF-12 five times, and all five time 
points have been used in the present study. 
 
3.7 Ethical considerations 
The study was approved by the Regional Committee for Medical and Health Research 
Ethics (REK) (154-081158d 6.2008.547), the Norwegian Directorate of Health 
(08/6788), the Privacy Protection Committee at the hospital (08/1194), and the 
institutional review board at the Norwegian Radium Hospital. 
In the first application to REK, the follow-up period was planned to be 12 
months. However, REK considered that participation in a study for such a long period 
was a potential burden for patients, and the study was only given permission for a 6-
month follow-up period. This compromised the data from the study, as we were 
interested in long-term symptoms and QOL. 
When recruited to the study, the patients were first asked by the staff if they 
wanted to receive information about the study, and even receiving information about 
the study was therefore voluntary. The recruitment team was not allowed to access 
the medical files with the purpose of identifying patients who met the inclusion 
criteria of the study; therefore one of the staff had to identify the eligible patients 
from the medical files. 
The PhD student or a research nurse obtained informed consent before the 
start of RT. All patients who were invited to participate had the opportunity to 
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consider the issue for more than 24 hours before they signed the consent form. The 
consent form included the date and signature. The patients were informed that they 
could withdraw from the study at any time during the study period, without giving 
reasons.  
Data protection was looked after in the present study. When patients had 
signed the consent form, they were all given a unique study identity number. All 
patient information (i.e., questionnaires, CRFs) was treated without personal data 
(i.e., national identity number) or other information that could identify the patients. 
The unique study identity number was used on all data, and the codebook that 
coupled the study identity number to the patients, was locked into a separate locker 
from the data.    
 
3.8 Statistics 
3.8.1 Overall considerations 
Paper I in this dissertation was limited to baseline data, while paper II and III present 
longitudinal data over six months. 
Mixed-model analyses were used for the longitudinal analyses in this 
dissertation. The models in mixed-model analyses consist of subject-specific effects 
(mixed effects). The analyses further allow for unequal number of observations on 
each subject, meaning that a complete dataset was not required for running the 
analyses (96). The mixed-model analyses were also used because of the repeated 
measures (more than one for each individual) and since the missing data were 
considered as missing at random (96;97). Cases with a lot of missing data on a 
predictor were dropped from the analyses. Mixed-model analyses allow the use of 
all observations even if some assessments are missing, but only for the dependent 
variable. Missing data were further handled as described for each instrument.  
In papers II and III, different mixed-model analyses were used to investigate 
changes over time for specific symptoms and QOL, respectively. In paper II, two 
different multilevel generalized linear models were used: multilevel logistic 
regression was used to investigate symptom occurrence longitudinally while severity 
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and distress were examined using multilevel proportional odds ordinal logistic 
regression because they both are coded as ordinal variables. For paper III, random 
intercept and slope models were used to analyze changes in QOL during the six 
months, as these models have become the standard way of analyzing continuous 
longitudinal data. 
All analyses were done using SPSS Version 16-18 (SPSS Inc, Chicago, IL, USA), 
Stata Version 11.0- 11.1 (Stata Corp, 2010) (98;99). The multilevel ordinal regression 
models were estimated with gllamm, a user-written program for Stata, downloaded 
within Stata with “findit gllamm”(100).  The figure was made in Microsoft Excel for 
Windows (2003). For all tests, a p-value of <0.05 was considered as statistically 
significant. 
 
3.8.2 Sample size calculation 
As this study is part of a larger cohort study, the sample size was based on genetic 
tests from blood samples in the total sample. A sample size of 500 in the larger 
cohort study would give greater than 80 % power to detect a significant difference 
(α=0.05), and the presented p-values were two-sided. Specific sample size 
calculations are not recommended after data collection (101) and they were not 
performed for the subsample analyses presented in this dissertation.  
 
3.8.3 Paper I – analyses 
In the current paper, baseline data from the MSAS and the SF-12 in addition to 
medical and socio-demographic data were used. 
Descriptive statistics were used to present demographic and clinical 
characteristics of the data, and independent t–test and exact chi square were used 
to test for differences between patients who did and did not receive CTX prior to RT. 
A negative binomial regression was performed to investigate the variables that 
influenced the total number of symptoms at baseline. Negative binomial regression 
was chosen rather than Poisson regression because the distribution of the symptoms 
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reported by the patients was strongly right–skewed with over–dispersion (the 
variance was greater than the mean). Selected variables (demographic and clinical) 
were examined, and variables that had a bivariate association (Pearson correlation) ≥ 
than .20 with the dependent variable (total number of symptoms) were selected for 
joint entry into the regression analysis based on the belief that this level of 
association was meaningful in this exploratory study (102). The variables 
investigated for the model were age, level of education, employment, KPS, time 
since surgery, comorbidities, and type of surgery (i.e., ALND, BCS, SLNB, 
mastectomy). The stage of disease was not entered into the regression analysis 
because of its high correlation with other covariates (i.e., ALND, CTX). The variable 
selection was both empirically and theoretically driven. To construct a model that 
was parsimonious, variables were removed one at a time following the 
recommendations of Hosmer & Lemeshow (2000) until only significant predictors 
remained in the final model (103). The Benjamini–Hochberg method was used to 
correct p-values for multiple testing. This is a less conservative test for multiple 
testing than the more familiar Bonferroni– test (104). 
 
3.8.4 Paper II – analyses 
In paper II, MSAS data from all five assessment time points were used in mixed–
model analyses, to evaluate the occurrence, severity and distress of symptoms over 
time. The six symptoms that occurred in > 50% of the patients at the initiation of RT 
(i.e., lack of energy, worrying, difficulty sleeping, feeling drowsy, sweats, pain) were 
evaluated in the longitudinal analyses 
Symptom occurrence was coded as a binary variable (yes = 1, no = 0) and 
examined using multilevel logistic regression, while symptom severity and distress 
items were coded as ordinal (i.e., 0 = not present and with severity/distress ratings 
increasing from 1 to 4 and from 1 to 5, respectively) and were examined using 
multilevel proportional odds ordinal logistic regression (105-109). Demographic and 
clinical variables that had a bivariate association (r) of ≥ .20 with the total number of 
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symptoms at baseline (i.e., age, KPS score, SCQ score, ALND, previous CTX treatment) 
were selected for evaluation as predictors in the regression models. 
For both types of models, the first assessment was treated as baseline 
(intercept) for the growth trajectory. Unconditional models were examined first to 
estimate the linear change in the symptom reports. Given the possibility that the 
change was not only linear, quadratic effects were examined. The change trajectory 
for lack of energy had two segments: baseline to two months and two to six months. 
Further, the change trajectory for feeling drowsy had three segments: baseline to 
one month, one month to three months, and three to six months. Therefore, 
piecewise models were examined for lack of energy and feeling drowsy (110). The 
other four symptoms were best fit with linear trajectories. 
After the best fitting growth trajectory for each symptom had been 
identified, conditional models were used to examine the associations for each of the 
covariates (i.e., age, KPS score, SCQ score, ALND, previous CTX treatment) on the 
reported symptom dimensions at baseline and on the change in symptom 
dimensions over time (cross-level interaction). Two of the covariates (i.e., KPS, age) 
were reverse coded to make interpretation easier.  
 
3.8.5 Paper III – analyses 
SF-12 data from all five assessment time points were used. Random-intercept and 
slope models (mixed models) were used to estimate linear trends for each of the 
MCS and PCS of QOL. Two random-intercept and slope models were fitted for the 
periods from baseline to two months and from two to six months, because of the 
non-linear effect of the time variable. 
Variables were selected for the mixed model analyses based on p-values from 
bivariate analyses (Pearson correlation) in combination with clinical considerations. 
All of the variables were entered into the initial model, and all variables that were 
selected for inclusion in the multivariate analyses of association were kept in the 
model, to adjust for possible confounders. For the symptom variable, the mean 
occurrence rate for the total number of symptoms was used. The stage of disease 
was not entered into the initial models because of its high correlation (r ≥ 0.6) with 
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other treatment variables (i.e., ALND, mastectomy, BCS, CTX). Variables describing 
the type of surgery were also highly correlated (r ≥ 0.6) with each other, and only 
one of the three variables (i.e., ALND, mastectomy, BCS) was included in the initial 
models. Mastectomy was included in the model describing the MCS, and ALND was 
included in the model describing the PCS. The rational for including different 
variables in the two models were based on the knowledge that body image is an 
issue in women undergoing mastectomy and is therefore important as a predictor 
for the MCS (64;111-113) and that ALND is associated with an increased number of 
symptoms and lower arm morbidity (113), and as such was investigated as a 
predictor for the PCS.  
A series of random–intercept and slope model was used to examine the 
contribution of the independent variables to the trends of both MCS and PCS. A 
likelihood ratio test, using the maximum likelihood method, was performed for 
variables with p-values ≥ 0.05 in the model, to identify whether a variable 
contributed to the model even if it was not significant. The presented values were 
adjusted for the covariates in the models. 
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4.0 Results 
4.1 Participants 
In the main cohort study, 613 patients and 278 family caregivers were included. 
Women with breast cancer (n=188) recruited for the main study were included for 
the secondary analyses undertaken for this doctoral dissertation. 
As described in the flowchart below (Figure 2), 245 women were eligible for 
participation in the study, and 211 (85 %) signed the informed consent form. Two of 
the included patients did not have breast cancer, and they were therefore excluded 
from the study. For the 34 patients who declined participation, the most common 
reason given was that they did not like questionnaires or they did not have the 
energy to fill out the questionnaires. Finally, 188 patients (76 %) filled out the 
baseline questionnaire while 21 patients never returned it, or withdrew before they 
filled it out. One patient died from the index tumor during the study period. In the 
inclusion criteria for this study, it was not specified that the women had to be 
scheduled for post-operative RT, and three women with metastatic disease were 
included in the study. These patients received a different total dose of RT (30 Gy) 
compared with the women who were scheduled for post-operative RT (50-60 Gy); 
the mean value of the total sample was 49.6 (SD 2.6) Gy. 
The sociodemographic and clinical characteristics of the participants are described in 
Table 3. The mean age of the patients in the study was 57.7 years (SD = 9.2), and the 
patients who declined participation were significantly older (mean age 61.5 years, SD 
= 10.8, p = 0.015) than the patients who agreed to participate. The majority of the 
women were married or living with a partner and had a primary or secondary level of 
education. The majority had stage I or II of the disease, while eight patients did not 
have a TNM classification, and five patients had cancer in both breasts. 
Approximately half of the women in the sample had received CTX at the time of their 
inclusion in the study. Most of them had undergone BCS while 36 % had undergone 
mastectomy, and six patients had undergone both BCS and mastectomy. When the 
women were recruited to the study, the mean time since surgery was 168 days (SD = 
518). Of the 10 patients who had already received RT, seven patients had breast 
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cancer in the collateral breast, while palliative RT for metastatic disease was planned 
for three patients. 
 
Table 3 Demographic and Clinical Characteristics 
 
Characteristics Mean (SD) Range 
Age (years), 57.8 (9.2) 27-81 
Baseline KPS 88.0 (11.0) 40-100 
Baseline SCQ-19 score   3.3 (3.3) 0-18 
Baseline total number of symptoms   9.4 (7.1) 0-32 
 N % 
Education   
Primary and Secondary 116 65 
College/University 63 35 
Marital Status   
Married/living with partner 137 73 
Unmarried/divorce/widow 50 27 
Employment Status   
Employed 15 8 
Not employed 167 92 
Stage of disease   
Stage 0/DCIS 17 9 
Stage I 70 39 
Stage II 68 38 
Stage III 25 14 
Type of Surgery   
Breast conservative surgery 126 67 
Mastectomy 68 36 
Sentinel lymph node biopsy 140 75 
Axillary lymph node dissection 95 51 
Previous Treatment   
Hormonal therapy 5 3 
Radiotherapy 10 5 
Immunotherapy 5 3 
Chemotherapy 86 46 
Abbreviations: DCIS: Ductal Carcinoma In Situ, SCQ: Self-Administered 
 Comorbidity Questionnaire, KPS: Karnofsky Performance Status Scale 
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4.2 Compliance 
The overall dropout rate during the study period from baseline to six months (Time 
5) was 16 % (n = 31) (Table 4). Most patients dropped out between the baseline 
measurement (Time 1) and 1 month (Time 2), which was approximately three weeks 
after the start of RT. 
Each of the questionnaires had data missing for 0-10 % of the items, and the 
items missing were equally distributed among the questionnaires and over time. The 
items missing on each questionnaire on each measurement points are outlined in 
Table 4. 
 
 
 
Figure 2 Flowchart of participants 
  
Eligible patients 
n = 245  
Included patients/ 
Signed consent form 
n = 211 
Time 1 
188 patients filled out baseline 
Declined participation 
n = 34 
Excluded 
Not breast cancer n = 2 
Withdrew or no 
baseline data n = 21 
Time 2 
175 patients 
 
Time 3 
170 patients 
Time 4 
164 patients 
Time 5 
157 patients 
Withdrawal n = 13 
Withdrawal n = 5 
Withdrawal n = 6 
Died n = 1 
Withdrawal n = 6 
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Table 4 Compliance – Overall and for the specific questionnaires 
 
  
Time Point 
1 
Time Point 
2 
Time Point 
3 
Time Point 
4 
Time Point 
5 
  
            
Participants 188  175  170  164  157  
            
SF-12 174  165  159  159  153  
            
MSAS 183  175  170  164  157  
            
SCQ-19 179  - - 162  151  
            
KPS 177  160  160  159  151  
Abbreviations: SCQ: Self-Administered Comorbidity Questionnaire, SF-12: Short Form-12,  
KPS: Karnofsky Performance Status Scale, MSAS: Memorial Symptom Assessment Scale 
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4.3 Summary of papers – main results 
The following pages summarize the main findings from each study (paper I-III) in the 
dissertation. Each paper describes the results in greater detail. 
 
4.3.1 Paper I 
Previous chemotherapy influences the symptom experience and quality of life of 
women with breast cancer prior to radiotherapy  
 
The difference in symptom occurrence, severity, and distress of multiple symptoms 
between women with breast cancer who did and did not receive CTX prior to RT was 
analyzed in the first paper of this dissertation. Furthermore, the paper investigated 
the difference in QOL between women who did and did not receive CTX and the 
relationship between the various demographic and clinical characteristic and the 
total number of symptoms.  
Women starting RT suffer from multiple symptoms (mean = 9.4, SD 7.1) and 
women who have received CTX prior to the start of RT have twice as many 
symptoms (mean = 12.6, SD 7.1) than women without CTX (mean = 6.5, SD 5.8). 
Previous CTX, a lower KPS score, and higher comorbidity profile were significant 
predictors for higher numbers of symptoms. More than 50 % of the total sample was 
experiencing lack of energy, worrying, difficulty sleeping, feeling drowsy, sweats and 
pain. Lack of energy, feeling drowsy, dry mouth and numbness/tingling had 
significantly higher occurrence rates for women who had received CTX, and were 
frequently reported (59 % – 79 %) in these women. No changes were found in the 
severity and distress score for the symptoms between the two treatment groups, 
except for the severity of hair loss, changes in skin, and difficulty swallowing. The 
latter symptoms had significantly higher severity scores among the women who had 
received CTX prior to RT. Women who had received CTX prior to RT also had a 
significantly lower SF-12 PCS before commencing RT, while the MCS scores were 
similar to those of the women who had received CTX. Compared with Norwegian 
normative data, the participants had significantly lower scores. 
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4.3.2 Paper II 
Changes over time in occurrence, severity, and distress of common symptoms 
during and after radiotherapy for breast cancer  
 
Changes over time in occurrence, severity, and distress of the six most prevalent 
symptoms at baseline (lack of energy, worrying, difficulty sleeping, feeling drowsy, 
sweats, and pain) were investigated during and after the course of RT in the second 
paper of the dissertation. In addition, the impact of five demographic and clinical 
characteristics (higher age, decreased functional status, higher number of 
comorbidities, ALND, and previous CTX) on the symptoms and the various 
dimensions was investigated. 
The trajectory for the occurrence, severity, and distress for each symptom 
followed similar patterns through the study period (six months) for all symptoms 
investigated. Lack of energy, feeling drowsy and worrying changed in all three 
dimensions over time, while no changes was seen for the symptoms difficulty 
sleeping, sweats and pain. 
Lack of energy increased significantly from baseline until two months (Time 
3), and then decreased from two to six months (Time 5). All five covariates (higher 
age, decreased functional status, higher number of comorbidities, ALND, and 
previous CTX) increased the likelihood of reporting the symptom at baseline. 
However, for the patients who had received CTX and ALND, the likelihood of 
reporting lack of energy at baseline was much higher than for the women who had 
not previously received CTX or ALND. For the women who had received the 
treatment, the likelihood of reporting the symptom decreased steadily until six 
months. Similar patterns were also seen for the severity and distress of the 
symptom. 
The women also reported a significant change in feeling drowsy over the six 
months. The likelihood of reporting feeling drowsy increased over the first month 
(Time 2), then decreased radically from month one to three (Time 2 to 3), and then 
decreased slowly from month three to six (Time 3 to 5). Having received CTX was the 
strongest predictor for change in the symptom. Women who received CTX had a 
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higher likelihood of reporting feeling drowsy at baseline, and had only a weak 
increase from baseline until 1 month. Women who had not received CTX had a 
radical increase in the likelihood of reporting the symptom from baseline until 1 
month. Similar patterns were also seen for the severity and distress of the symptom. 
The likelihood of reporting worrying was found to decrease from baseline 
until six months in the present study, for all three dimensions of the symptom. 
Younger women were more likely to report the symptom and to report higher 
severity and distress related to the symptom. A lower KPS score, higher comorbidity 
score, and having received CTX and ALND were also associated with a higher 
symptom burden. 
The overall effect of the five covariates was increased symptom burden 
across all three dimensions. 
 
4.3.3 Paper III 
The relationships between demographic and clinical characteristics and quality of 
life during and after radiotherapy – in women with breast cancer 
 
QOL was assessed using SF-12, before, during, and after the course of RT, and the 
risk factors for reduced QOL in women with breast cancer were identified. 
The mean PCS did not change significantly (p = 0.08) during this period. 
However, the analyses identified three covariates as significant negative predictors 
(p ≤0.05) of the PCS over the 6 months (i.e., higher comorbidity score, higher 
number of symptoms, and lower KPS score) after adjusting for statistically and 
clinically significant covariates. A higher number of symptoms and a higher 
comorbidity profile were negative predictors for the PCS level, while an increase in 
the KPS score was a positive predictor for a higher PCS during the six months of the 
study. 
The MCS did not change between baseline and the 2-month assessment but 
the final model of the MCS revealed that four covariates were significant predictors 
of change in MCS in this period (i.e., CTX, higher number of symptoms, higher age, 
and education). A higher number of symptoms and higher age predicted worse MCS, 
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while having a college or university degree compared with a primary/secondary 
education and having undergone CTX was associated with an increase in MCS, for 
the first two months.  
In the period from two to six months after the initiation of RT, MCS increased 
significantly. In the final model of the MCS for this period, two of the same and two 
different covariates were significant predictors of change (i.e., total number of 
symptoms, age, KPS, and time). A higher number of symptoms and higher age 
predicted worse MCS, while increased KPS and time since the start of RT predicted 
an increase in MCS. 
In summary the MCS and PCS of QOL remained stable at a diminished level 
up until two months after inclusion. PCS remained stable while MCS improved. The 
total number of symptoms and age were significant predictors for change in both 
component scores (MCS and PCS) during the six months. 
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5.0  Discussion 
The discussion part of this dissertation will be organized according to two main 
issues: the methodological issues of the study and the main results from the papers. 
 
5.1 Methodological discussion 
5.1.1 Design  
A longitudinal design with repeated assessments in the same cohort was considered 
the most appropriate to meet the aims of the present study. We believe the time 
dimension is of importance for both the symptom experience and QOL. The original 
design was a one-year follow-up, to capture more of the longitudinal perspective 
after treatment, in order to differentiate chronic from acute symptoms after cancer 
treatment. The latter distinction is also important in planning symptom management 
strategies.  When the longitudinal design was not allowed, the time points were 
selected to best capture the expected changes in the outcome measures over six 
months (i.e., symptoms and QOL). We were trying to capture maximum toxicity from 
RT from Time 2 and 3, while the longitudinal perspective as well as the effect of 
rehabilitation after RT was assessed at Time 4 and 5. We believe the longitudinal 
perspective was important to differentiate chronic from acute symptoms after 
cancer treatment and is further important for the development of more targeted 
symptom management strategies. 
Having a control group of women with breast cancer who did not receive RT, 
enabling comparison of the symptom burden and QOL between women who did and 
did not receive RT, would increase the probability of identifying the symptoms that 
were directly associated with RT alone.  However, this was not possible, because 
such a control group did not exist, and control groups are seldom used in cohort 
studies. As a substitute to having a control group, one alternative could have been to 
compare the results with age-matched data from the normal population. However, 
this was only done in paper I of the study. Paper III investigated QOL longitudinally 
during RT, and the results were therefore not compared with the normal population. 
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In addition, the use of the norm-based score of the SF-12 incorporates comparison 
against normal population in the scoring algorithm. The baseline data were used as 
controls for the longitudinal data. However, at baseline the women had already 
undergone several treatments (e.g., surgery, CTX, hormonal therapy), and the 
baseline measurement in our study is probably influenced by previous treatments. 
When analyzing the data we controlled for previous treatments, as some symptoms 
may be related to the previous treatment rather than to the RT in itself. 
The longitudinal design strengthens the present study compared to a cross-
sectional design with analyses of patient groups in different parts of the treatment 
and follow-up period. In cross-sectional design the ability to use the individual 
patients’ baseline as a control is lost. 
 
5.1.2 Patient recruitment, compliance and representativeness  
Unfortunately, not all available patients were recruited into the study. The reasons 
for rejection are important when planning new studies, but REK does not allow 
systematic collection of this information, to protect the patient. Even though we did 
not ask the patients why they said no to participation, several patients 
spontaneously explained the reason, and the most common reason were that they 
did not have the energy to participate, or that they did not like questionnaires.  
Since women with breast cancer had the simulation visit for radiation 
planning (the time of inclusion) only twice a week and they all met with a nurse on 
that day, we were able to invite all patients who met the inclusion criteria of the 
study to participate. For the patients who had agreed to participate but did not 
return the baseline questionnaire, a reminder letter was sent to their home address. 
To improve compliance for the recruited patients at baseline, help to fill out the 
questionnaires was offered, but most patients preferred to fill them out at home.  
The patients could say no to receiving information about the study, but very 
few did that. This study had a participation rate of 76 %, which may be related to the 
time of inclusion (prior to RT). The women who declined participation may have felt 
exhausted from previous treatment and the disease in itself, or felt anxious for the 
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RT that they were about to commence. The participation rate is comparable to other 
studies investigating QOL (61;68;69;114).  
However, the fact that nearly one out of four patients who met the inclusion criteria 
declined participation is of importance for the interpretation of the data. Some 
information about the non-participants was available. The patients who declined 
participation were significantly older (p = 0.015) than the study participants and 
were likely to be more exhausted from the disease and its treatment and might have 
had more comorbidities and poorer health than the participants did. 
The 16% attrition rate during the follow-up was as expected, and was found 
to be comparable to other studies (66;68;114). As compliance is of major importance 
in longitudinal studies, different procedures for the follow-up period were 
implemented, to ensure best possible compliance. All eligible patients who were 
asked for participation were also given the phone number of the study nurse, so 
they could easily get help if they had any questions when filling out the 
questionnaires. For all time points, the questionnaires were sent by postal mail to 
the patients, including an explanatory letter and a prepaid return envelope. To 
improve compliance, the patients were allowed to bring the questionnaires to the 
hospital when they were there to receive treatment. Finally a reminder letter 
including a new questionnaire was sent for each time point, if we did not receive the 
new questionnaire within two weeks. 
It is important to know which patients dropped out of the study, and if they 
differ from the ones that remain in the study. Previous studies have demonstrated 
that those who drop out differ from the participants in that they suffer more, and 
therefore they do not fill out questionnaires or they drop out of the study (114-116). 
Missing data should therefore be considered different from non-missing data. Still, 
dropout over time must be expected in longitudinal studies. 
In the present study, the level of missing data was similar for all assessment 
points, and therefore we treated the data as missing at random (115;116). Patients 
who did not fill out the last questionnaires had a higher number of symptoms at the 
end of RT (Time 3) implying that the patients that dropped out might have been the 
ones who suffered the most. This is of importance when interpreting the data. The 
symptom burden and reduction in QOL might have been underestimated. As it is 
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difficult to avoid missing data in longitudinal clinical studies, it is important to select 
statistical methods that allow for incomplete data such as the mixed model analyses 
used for the longitudinal data in the present study.    
The recruiting RT center treats women with breast cancer from a large 
geographical area based on the Norwegian Breast Cancer Group (NBCG) guidelines 
for RT (27). The results should therefore be generalizable to a larger population of 
women with breast cancer receiving postoperative RT. In addition, the sample is 
comparable with samples in other studies investigating symptoms and QOL for 
women receiving RT for breast cancer (40;64).  
 
5.1.3 Psychometric properties of the instruments  
We believe the content validity of the instruments used in the present study was 
satisfactory. For the SF-12, relevant segments of what defines QOL are included in 
the questionnaire (e.g., mental and physical). Both the SF-12 and the KPS are 
extensively used in research, and both have a well-known and satisfactory content 
validity. For the SCQ and MSAS, the number and nature of the symptoms and 
comorbidities were important for the choice of those instruments in the present 
study. We believe that the comprehensive list of cancer-specific symptoms made the 
MSAS relevant for the present study. The SCQ also had a comprehensive list with the 
most common diseases, including the opportunity to fill in three additional 
comorbidities, if they were not on the list.   
A generic QOL questionnaire was used because the larger cohort study 
included patients with different cancer groups. A cancer-specific questionnaire could 
have been used, as all patients had a cancer diagnosis, but this would made 
comparison across other diagnoses more difficult. A disadvantage of using a generic 
instrument is that it could be less sensitive for change for our study sample, as issues 
specific to breast cancer are not included in the questionnaire. A breast-cancer-
specific questionnaire could have been added, to avoid the potential loss of 
information associated with the use of a less sensitive instrument. However, due to 
the already high number of questionnaires, a breast-cancer-specific questionnaire 
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was not added to the package in the present study. It was considered important not 
to give the patients too many questionnaires as they were in a vulnerable period of 
their lives. 
Several strategies were used to ensure reliability in the present study. First, 
all the instruments (i.e., SF-12, KPS, SCQ, and the MSAS) that were used in the 
present study are well-known and have been used extensively in previous trials with 
satisfactory reliability (36;57;72;73;78). All Norwegian versions of the inventories 
have also been used previously, except for the MSAS, which was translated as part of 
this study using recommended guidelines (89). A pilot test of the questionnaires was 
conducted, to ensure appropriate layout, to test the combination of several different 
inventories, and to test the Norwegian version of the MSAS. Finally, the strategy for 
reducing random errors in the database was to double-check all data from the 
electronic database against hard copies. When errors were detected, all 
questionnaires for all five time points were double-checked and corrected against 
the hard copies, to ensure that no errors were introduced. 
Cronbach’s alpha is the most commonly test for internal consistency, and as 
described previously, Cronbach’s alpha is not commonly used for the instruments 
used in the present study (SF-12, MSAS, KPS, SCQ). Cronbach’s alpha was not used 
for the MSAS, SCQ or KPS in the present study because we did not expect internal 
consistency in a list of symptoms or comorbidities. Further, it is not possible to run 
Cronbach’s alpha for the KPS, because patients only tick one box, and internal 
consistency can therefore not be measured. The creation of the two component 
scores for the SF-12 is based on different weights, and the value of doing a 
Cronbach’s alpha test is therefore debated. A test-retest is an alternative test for 
internal consistency. This was not conducted in the present study, as the time 
interval was not appropriate, and change was expected due to treatment. Still, a 
test–retest situation could have been part of the pilot study if more patients had 
been included and had agreed to fill out some of the questionnaires twice. Another 
alternative could have been to ask a group of the included patients to fill out some of 
the instruments one extra time, with the purpose of testing the reliability. Despite of 
the lack of reliability testing in the present study, the instruments used all have well-
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established reliability, and have all been previously used in cancer populations 
(48;74;75;79;80;85;87;94). 
5.1.4 Memorial Symptom Assessment Scale (MSAS)  
The MSAS captures the complexity of symptoms by including the multidimensional 
aspects of each of them (e.g., occurrence, frequency, severity, distress). This is an 
essential feature in the choice of symptom inventories.  However, even though the 
32 symptoms could be regarded as typically cancer-related, the instructions for the 
instrument do not specify that only symptoms related to the cancer diagnosis or its 
treatment should be reported. Patients have therefore reported all symptoms they 
experienced, and not only cancer-related symptoms. This introduced a potential bias 
to the dataset, as the intention of the study was to describe symptoms related to the 
cancer diagnosis or its treatment. However, we believe that in the investigation of 
changes in symptoms during cancer treatment, ‘chronic’ symptoms remained more 
stable, and we were therefore able to capture the changes in important cancer-
related symptoms. Further, the comorbidity variable was used in the interpretation 
of the symptom data at baseline, to control for this potential bias. 
The layout of the MSAS has some limitations, because the lines are narrow and there 
are massive amounts of text. To correct for this limitation, if patients had indicated 
the frequency, severity or distress of a symptom they ‘did not have’, we coded the 
response as if the patient had the symptom; see appendix. When treating the data as 
described, we detected missing data for 5-10 % of items during the study period for 
the MSAS. 
When creating the variable ‘total number of symptoms’ we had a liberal 
approach when summarizing the number of symptoms for each patient. If the patient 
had only described one symptom on the MSAS, the total number of symptoms was 
coded as one. We believe this approach was appropriate for interpreting the data in 
the present study, without compromising the validity. The frequency dimension was 
not used in our data analyses due to the already high number of variables, and the 
fact that the severity and distress dimensions already captured important aspects of 
the symptom experience. 
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5.1.5 Short Form 12 (SF – 12)  
Even though the SF-12 is empirically developed (90), the instrument includes eight 
dimensions (i.e., physical functioning, role-physical, bodily pain, general mental 
health, vitality, social functioning, role-emotional, mental health) that are usually 
part of the concept of health related quality of life and reflect the QOL definitions of 
Ferrans (1990) as well (55). 
The fact that the questionnaire is a generic QOL questionnaire makes it easier 
to compare results across diagnoses, which was an important aspect for the main 
study. However, due to the lack of disease-specific aspects of QOL, the sensitivity to 
changes over time might have been reduced.  Some controversies exist regarding the 
assumption of non-correlation between the MCS and PCS (117-119) in the scoring 
manual of the SF-12. The opponents of the original scoring manual state that MCS 
and PCS cannot be separated, as the dimensions are correlated in the real world, and 
that the current scoring algorithm may lead to opposite levels in the extreme values 
(117;119-121). The developers of the instrument argue for the choice of orthogonal 
factor rotations, as a way to avoid double loading of scores on both dimensions, and 
still maintain the highest amount of variance in each scale (92). We have reflected on 
this potential problem for our data, and believe that the possible bias imposed by 
the use of orthogonal factor rotations is fairly stable, and that our longitudinal data 
on changes over time will not be compromised due to the assumption of 
uncorrelated sum scores. 
 
5.1.6 Self-Administered Comorbidity Questionnaire (SCQ – 19)  
The self-reported questionnaire for comorbidities (SCQ-19) was selected rather than 
collecting the information from the medical records, as research has shown that 
patients can accurately assess their medical condition (78). The patients had the 
opportunity to add three additional comorbidities, which reduced the chance of 
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leaving out any conditions. Another advantage of the SCQ-19 was that it allowed the 
women to describe the severity and the impact of their comorbidities (78).  
As certain comorbid conditions typically do not limit a person’s overall function, 
while others may impose severe functional limitations, we believed a sum score 
most accurately describes the burden of comorbidities. 
 
5.1.7 Data analyses  
The dissertation presents results from analyses on both cross-sectional and 
longitudinal data. For the longitudinal data, the end points (i.e., symptoms and QOL) 
were measured with both categorical (i.e., occurrence, severity, distress of 
symptoms) and continuous data (i.e., QOL and total number of symptoms), therefore 
different analytic approaches were used. All data analyses have been conducted with 
close collaboration with statisticians to ensure best possible quality. Due to the high 
number of variables in paper I, correction for multiple testing was considered 
appropriate. In papers II and III, only a small number of variables were investigated, 
and it made more sense to evaluate each predictor on its own. Correction for 
multiple testing was therefore not conducted (122).  
An important reason for using mixed-model analyses in the present study is 
that they allow for incomplete data sets, as will always be the case in longitudinal 
designs, also for the present study. This means that all the available data are used, 
which also increases the generalizability of the study, as the results are based on all 
participants in the study, and not only those with complete data. 
 
5.1.8 Theory of Unpleasant Symptoms  
At the start of the study, the Theory of Symptom Management (TSM) was used. 
However, based on our research questions, and the focus on the multidimensional 
aspect of the symptoms and their predictors, the TOUS was used for the last two 
papers and for the analyses and interpretation of the data in the dissertation. The 
TOUS has been a helpful tool in identifying the elements of the individual symptoms, 
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understanding the interactions among symptoms, and distinguishing the different 
influencing factors of a symptom. Furthermore, the model has been of great 
importance in planning of the statistical analyses that investigated covariates of the 
symptom burden.   
In the model, the influencing factors are described as influencing each other 
as well as the symptoms. In our study, this means that the experience of receiving RT 
(physiological factor) is influenced by both situational factors (e.g., personal 
relationships) and psychological factors. Similar situational factors may have 
different impacts on the symptom experience as well as on the other situational 
factors. They must therefore be described on an individual level, as in the present 
study. For instance, personal relationships can be an asset (e.g., social network, 
partnership) or something that increases the negative experience of a symptom 
(e.g., lack of social network, loneliness). 
The TOUS has been helpful in understanding the interaction of those factors 
and its importance for the symptom experience. In symptom research, it is therefore 
essential to include the situational factors in the data collection, as we did in the 
present study. The TOUS further describes how the symptoms and the various 
dimensions are influenced by these three factors. Despite the fact that the figure 
does not include arrows between the various dimensions of the symptoms, the 
model acknowledges that the dimensions are related to each other (Figure 1).  
In the present study, QOL was used as an outcome measure for performance 
outcome. The feedback effect of QOL on the symptoms and the situational factors 
was not investigated in the present study, even though we acknowledge that 
according to the model, the symptom experience is a continuous process, and QOL 
has a feedback effect on both the symptoms and the situation factors. However, 
investigating those relationships was not part of our research questions.  
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5.2 Main results 
The discussion about the results from this study will be organized according to the 
main findings. 
 
5.2.1 High symptom burden before radiotherapy  
A recent study by Deshields et al. (2014) (123) also used the MSAS to investigate the 
persistence of symptom burden across one year in a heterogeneous (i.e., breast, 
colorectal, gynecological, lung, and prostate cancer) sample of cancer patients. The 
women with breast cancer from the latter study reported an average of 11.2 
symptoms (SD 8.1) at baseline, while the average number in the present study at 
baseline was 9.4 (SD 7.1). However the amount of treatment the patients had 
received at baseline was not similar for the two studies. 
Of the six most prevalent symptoms before starting RT (lack of energy, 
worrying, difficulty sleeping, feeling drowsy, sweats, and pain), only difficulty 
sleeping was also reported as one of the most severe and distressful symptoms 
(paper I). On the other hand, ‘hair loss’ was described as the most severe symptom, 
while ‘problems with sexual interest’ was described as the most distressing symptom 
before starting RT (paper I). These findings highlight the challenge of symptom 
management: should the interventions be targeted toward diminishing the severity 
or the distress of the symptoms? In the original paper by Portenoy et al. (36) the 
correlation between severity and distress of the symptoms is described as high (r = 
0.70), and reducing the experience of one of the dimensions might therefore reduce 
the other dimensions as well. For some symptoms, reducing the severity is 
impossible (e.g., hair loss); however, learning coping strategies to reduce the distress 
of the experience might be possible. This in turn highlights the need for symptom 
management strategies that target the specific dimensions of the symptoms directly. 
Strategies for reducing the severity of a symptom would probably be targeted 
towards reducing its strength (e.g., pain); however, the various symptoms would 
need different strategies. The distress dimensions according to the TOUS (23), 
describe the degree to which an individual is bothered with the symptom, and the 
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significance that the individual attaches to the symptom. Therefore, the symptom 
management strategies targeting the distress dimension would be more individual. 
In the theory of Symptom Management (70) the strategies are described as 
preventing, delaying or minimizing the symptom experience. This is further 
described as effective in three ways: by reducing frequency of the symptom 
experience, by minimizing the severity of the symptom, or by relieving the distress 
associated with the symptom. The theory highlights the increased attention given to 
self-management strategies used by the patients, thus shifting the responsibility of 
managing symptoms to the individual patient. Intervention studies using such 
strategies are warranted. 
Recent evidence suggests that the burden of experiencing multiple symptoms 
is higher than the sum of the actual number of symptoms (124;125), since one 
symptom may cause other symptoms, or a symptom may be perceived as worse 
when it occurs simultaneously with other symptoms. Therefore, describing multiple 
symptoms is necessary to understand which symptoms occur concurrently, and to 
understand the total symptom burden. 
 The present study adds further knowledge to the literature on the 
experience of multiple symptoms for women starting RT for breast cancer, in 
describing the high symptom burden these women are experiencing and the 
complexity of the symptom dimensions. Further, the present study highlights the 
importance of multidimensional symptom assessment to capture the symptom 
burden, and to target individual and adequate symptom management strategies. 
 
5.2.2 Similar pattern for the trajectory of occurrence, severity and 
distress  
When changes in the different dimensions of the most frequently occurring 
symptoms during the course of RT were investigated, surprisingly, similar patterns 
were found for the three dimensions (i.e., occurrence, severity, and distress) of the 
most common symptoms during RT. We believe there are different possible 
explanations for this finding. One is that the results accurately describe the nature of 
those specific symptoms for women receiving RT for breast cancer, and that the 
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trajectories would differ if other and more rarely reported symptoms had been 
investigated. Another possible explanation is that severity and distress dimensions 
are, as described by Portenoy et al. (1994,) highly correlated phenomena and 
typically follow similar trajectories. The findings of similar patterns in the three 
dimensions (i.e., occurrence, severity, distress) are still unique, as we have not been 
able to find any other studies that have investigated several dimensions of the most 
common symptoms longitudinally for women receiving RT for breast cancer.  
According to TOUS, there are important theoretical differences between the 
dimensions of a symptom, and the theory describes severity and distress as distinct 
but related dimensions of a symptom (23). The theory further recognizes the 
similarities of the dimensions, supporting Portenoy et al. (1994) who described the 
dimensions as highly correlated phenomena (36). On the other hand, the theory also 
describes the distinct differences between the two dimensions; where severity refers 
to the strength of a symptom while distress reflects the degree to which a patient is 
bothered by a symptom (23). The importance of the different dimensions of a 
symptom would probably vary between patients, based on their previous experience 
with the symptom and how the symptoms influence their lives. The symptom 
experience is likely to differ both between symptoms and between patients. Further 
research is needed in this area. 
The present study presents unique and new findings regarding the trajectory 
of the different dimensions for the most common symptoms during RT for women 
with breast cancer. The findings warrant replication in future research, where other 
and rarer symptoms should be investigated longitudinally, to see if they follow the 
same patterns for the different dimensions. 
 
5.2.3 The importance of chemotherapy on symptoms and quality of life  
One of the main findings from this study is the negative impact of CTX on both the 
symptom experience and QOL both at baseline and over time. We also found CTX to 
be negatively related to the mental health dimension of QOL. 
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The symptoms with significantly different occurrence rates between women 
who did and did not receive CTX prior to RT were mostly symptoms that Portenoy et 
al. (1994) described as physical symptoms (e.g., lack of energy, pain, dry mouth, 
numbness/tingling, I don’t look like myself, nausea, hair loss, constipation, shortness 
of breath, food tastes different, lack of appetite, swelling of arms and legs, diarrhea, 
mouth sores, changes in skin, problems with urination) (36). Surprisingly, the 
symptoms described as psychological (e.g., worrying, feeling nervous, difficulty 
sleeping, feeling irritable, difficulty concentrating) were not found to differ between 
the two groups at baseline (prior RT) even though the CTX patients had a more 
advanced stage of disease (paper I). The lack of differences in the psychological 
symptoms before start of RT may be explained by the different time since diagnosis. 
Patents who had received CTX had more time to cope with the diagnosis and its 
treatment. This finding may indicate that there is no clear relationship between a 
high number of physical symptoms and psychological distress. However, no 
conclusions can be drawn from the present study, only presenting cross-sectional 
data, as more sophisticated statistical analyses should be used to further investigate 
the relationship between a high number of symptoms and psychological distress. 
Still, the importance of addressing psychological distress in women with breast 
cancer has been established in a recent study (126) where women with breast 
cancer were screened for psychological distress using an emotion thermometer. 
They found that the women experienced a high degree of distress or anxiety. This is 
also consistent with some previous reports (127-130). 
Interestingly, in paper I, we did not find that CTX increased the severity or 
distress of any of the MSAS symptoms at baseline except for three symptoms (hair 
loss, changes in skin, difficulty swallowing). This may suggest that having several 
symptoms does not necessarily increase the severity and distress of other 
symptoms. No other studies compared the severity and distress scores for symptoms 
experienced by women with breast cancer, based on CTX. However, investigation of 
the six most frequently occurring symptoms with more sophisticated analyses 
longitudinally and corrected for confounders (paper II) showed that CTX actually 
increased the likelihood of reporting higher severity and distress scores for some of 
the symptoms both at baseline and over time (e.g., worrying, feeling drowsy, lack of 
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energy). This highlights the importance of the use of longitudinal data, and more 
advanced statistical analyses, as a way to utilize the data in the most accurate way, 
and to reduce potential bias. 
The occurrence rate for worrying reported in paper I was not significantly 
different at baseline between patients who had and had not received CTX. However, 
when we investigated worrying using mixed model analyses (paper II) and adjusted 
for the impact of other covariates, CTX was found to increase the likelihood of 
reporting worrying at baseline, including the likelihood of reporting a higher severity 
and distress score. The different results regarding the impact of CTX on worrying 
(paper I and II) are likely to be due to the use of descriptive statistics, in contrast to 
mixed model analyses. 
CTX was also found to be a significant predictor for the total number of 
symptoms prior to RT (paper I), as well as longitudinally (paper II) for some 
symptoms (worrying, difficulty sleeping, feeling drowsy). Still CTX, was not found to 
be negatively related to the PCS of QOL, when corrected for confounders (paper III). 
The fact that a higher number of symptoms was found to be related to reduced QOL 
(both PCS and MCS), and not to CTX, may indicate that it is not the CTX in itself that 
is of importance for QOL, but the symptoms following CTX that lead to diminished 
QOL. This finding requires attention when planning for appropriate interventions or 
management strategies for improving QOL for women receiving RT for breast cancer. 
This study only investigated predictors of the total number of symptoms at 
baseline (prior to RT) and not longitudinally. However, significant differences in the 
total number of symptoms between the group of women who had and had not 
received CTX were also found after six months in the present study (data not shown), 
and may indicate the prolonged effect CTX has on the symptom experience for these 
women. 
The present study highlights the huge impact CTX has for women with breast 
cancer, prior to, during and after the course of RT, by increasing the symptom 
burden for these women which again leads to diminished QOL. 
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5.2.4 Minimal change in quality of life during the course of radiotherapy  
One of the main findings reported in paper III was the minimal change in QOL during 
RT. This is in line with previous reports of QOL during the course of RT 
(59;60;62;65;131). One concern could be that the SF-12 is not sensitive to changes in 
QOL for these women during RT, and that a breast-cancer-specific tool could have 
captured a change. On the other hand, other reports investigating QOL during RT for 
women with breast cancer using a disease-specific QOL inventory (e.g., EORTC) 
(59;60;62;65), still found no changes in QOL during RT. We found PCS to be stable at 
a diminished level through all six months, below the average for the normal 
population, and PCS did not deteriorate additionally during RT. The total number of 
symptoms was highly related to poorer levels of both MCS and PCS, and the findings 
were consistent with some other reports (20;48;82;123). In the present study, the 
PCS remained at the same level, although the total number of symptoms decreased 
after six months. Other covariates are also important for explaining changes in PCS, 
and physical health captures more than the effects of symptoms. The MCS score, on 
the other hand, was found to be higher and to improve significantly during the study 
period in the present study compared to the PCS.    
A consensus on the-long term effect on QOL for breast cancer survivors was 
found in the literature across early (133) and late studies (133); no major differences 
between breast cancer survivors and healthy controls have been detected, except 
that cancer survivors report more physical symptoms (134).  In summary, the 
present study demonstrated that a reduction in the symptom burden after six 
months did not lead to increased PCS, and that PCS remained at a diminished level of 
QOL before, during and after RT. In contrast, the MCS increased despite a 
consistently high level of symptoms. 
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6.0 Main conclusions  
In this dissertation, symptoms and QOL for women receiving RT for breast cancer 
have been investigated. The main findings can be summarized as follows. 
 Women with breast cancer starting RT experience a high number of 
symptoms 
 The most frequent symptoms do not always cause the most distress 
 Women who have received CTX have twice as many symptoms as women 
who have not received CTX when starting RT 
 Having received CTX was found to be one of the most significant predictors 
for reporting a higher number of symptoms during RT 
 Symptoms most frequently reported followed similar trajectories for the 
occurrence, severity and distress of the symptoms during the course of RT 
 Having received CTX was the strongest predictor for the occurrence, severity 
and distress of the most commonly reported symptoms over time 
 QOL remained at a diminished level during the course of RT, except for 
mental health, which increased at the end of RT 
 A higher number of symptoms is highly associated with a lower QOL score 
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6.1 Implications for clinical practice  
These findings have important implications for clinical practice. First of all, 
multidimensional symptom assessment should be a part of the clinical routines for 
women starting RT for breast cancer. Patients should be asked to fill out a 
comprehensive symptom inventory (including various dimensions of the symptoms) 
before starting RT or other treatment. There are several different strategies to 
facilitate this, and the symptom inventories can also be completed electronically 
from home. However, assessing the symptoms without introducing symptom 
management strategies does not help the patients who are experiencing them. 
Therefore, symptom management strategies must be introduced to the patients in 
an early phase of the treatment process, and must be targeted to the different 
dimensions of the symptoms reported. Patients receiving CTX must be prepared for 
physical symptoms that follow the treatment and the trajectory of symptoms during 
the course of RT, and its possible effect on QOL. 
The predicting factors for a high symptom burden or the most frequently 
reported symptoms (i.e., worrying, difficulty sleeping, feeling drowsy, lack of energy, 
pain, sweats), should be used by health care providers to provide more personalized 
symptom management strategies for women with breast cancer during RT. Different 
symptoms require different symptom management strategies, and one cannot 
expect all symptoms to be eliminated. Still, management strategies should focus on 
how to reduce the symptom experience to a minimum and to help patients to cope 
with the symptoms they experience. 
 
6.2 Future research  
This dissertation has discussed the multiple dimensions of symptoms, the high 
symptom burden and its predictors, and changes over time in both symptoms and 
QOL during the course of RT for women with breast cancer. Future research should 
be divided into two segments: descriptive and experimental research. The 
descriptive research should focus on commonly used symptom management 
strategies, as there is little literature on this topic. Descriptive longitudinal studies 
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should also be used to get a deeper understanding of the synergistic effects some 
symptoms have on each other. The TOUS should be used in the planning process of 
such a study, to ensure that all interactions and feedback effects of the symptom 
experience are captured. However, and more importantly, experimental design 
should be used to evaluate appropriate interventions to manage different 
dimensions of frequently reported symptoms for women with breast cancer who are 
receiving RT. A control group receiving ‘standard symptom management strategies’ 
should be used as part of an intervention study, to test the effect of the 
interventions. Finally, a qualitative approach should also be used in future research 
to obtain more in-depth knowledge on the patient experience regarding symptom 
management strategies.   
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Kontor for klinisk forskning, Rikshospitalet HF
Vennligst fyll inn eller sett kryss ved det som passer
Mann
Kvinne
2.   Hvilket år er du født?
3.   Hva er din sivilstatus?
Ugift
Gift / samboer
Skilt
Enke / enkemann
4.   Hvordan bor du?
Bor alene
Bor sammen med noen
5.   Hvor mange barn har du daglig omsorg for?
 antall barn
Initialer:
Draft
Grunnskole 7-10 år (framhaldsskole)
Ett- eller toårig videregående skole, yrkesskole, real- eller middelskole
Artium, økonomisk gymnas, 3-årig videregående skole
Universitet og/eller høgskole opptil 4 år
Universitet og/eller høyskole mer enn 4 år
Hvis annet, spesifiser, inkl. hvor mange år
6.   Hvilken utdanning er den høyeste du har fullført?
      (sett bare ett kryss)
7.   Er du i arbeid utenfor huset for tiden?
      (sett bare ett kryss)
Ja, heltidsarbeid
Ja, deltidsarbeid
Sykemeldt (helt eller delvis)
Uføretrygdet
Alderspensjonert
Arbeidsledig
Hvis annet, spesifiser
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TILLEGGSSYKDOMMER (SCQ-18)
Det følgende er en liste over vanlige medisinske problemer.
Sett ett kryss for hvert problem om hvorvidt du har problemet nå (ja eller nei).
Hvis du HAR problemet, så svar på spørsmålene om behandling og aktiviteter
til høyre.  Hvis du IKKE HAR problemet, gå videre til neste problem.
1.   Hjertesykdom
2.   Høyt blodtrykk
3.   Lungesykdom
4.   Diabetes
5.   Magesår / magesykdom
6.   Tarmsykdom
7.   Nyresykdom
8.   Leversykdom
9.   Anemi eller annen blodsykdom
10.  Hodepine
11.  Depresjon
12.  Slitasjegikt / artrose
13.  Rygg / nakkesmerter
14.  Leddgikt / revmatoid artritt
15.  Sykdom i bindevev eller muskulatur
16.  Hudlidelser
17.  Andre medisinske problemer (angi)
   Har du
problemet?
HVIS JA:
Får du behandling
       for det?
      HVIS JA:
  Begrenser det
dine aktiviteter?Problem
Ja Nei
Ja Nei
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Ja Nei
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FUNKSJONSTILSTAND (KARNOFSKY)
Sett ett kryss i den ruten som passer best.
Normal, ingen plager eller subjektive tegn på sykdom
Klarer normal aktivitet, sykdommen gir lite symptomer
Klarer med nød normal aktivitet.  Sykdommen gir en del symptomer
Klarer meg selv, ute av stand til normal aktivitet eller aktivt arbeide
Trenger noe assistanse, men klarer stort sett å tilfredsstille egne behov
Trenger betydelig hjelp og stadig medisinsk omsorg
Ufør, trenger spesiell hjelp og omsorg
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SYMPTOMLISTE (MSAS)
Veiledning:  Vi har listet opp 32 symptomer nedenfor.  Les hvert av dem nøye.  Hvis du har hatt symptomet i løpet av
siste uken, la oss få vite hvor ofte du hadde det, hvor kraftig det var det meste av tiden, og hvor mye det plaget eller
bekymret deg, ved å sette ett kryss i den ruten du synes passer best.  Hvis du IKKE HAR HATT symptomet, sett ett
kryss i den ruten merket HAR IKKE HATT symptomet.
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Vanskelig å konsentrere seg
Smerter
Har lite energi
Hoste
Føler meg nervøs
Tørr i munnen
Kvalme
Søvnig, mye trøtt
Nummen / prikker i hender / føtter
Søvnvansker
Luft i magen / oppblåst
Problemer med vannlating
Kaster opp
Kortpustet
Diaré
Føler meg trist
Svette
Bekymrer meg
Problemer med seksuallyst /
aktivitet
I løpet av den
siste uken:
Har du hatt noen
av de følgende
symptomene?
      Hvis JA:
Hvor ofte hadde
du symptomet?
      Hvis JA:
Hvor kraftig var
symptomet, det
meste av tiden?
     Hvis JA:
Hvor mye plaget
eller bekymret
symptomet deg?
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
Svæ
rt  
kraftig 
Kraftig 
Moderat 
Svakt 
Nesten  
hele tiden 
Ofte 
Av og til 
Sjelden 
H
ar ikke hatt sym
ptom
et
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SYMPTOMLISTE (MSAS) - del 2
Kløe
Manglende matlyst
Svimmel / ør
Vanskelig å svelge
Føler meg irritabel
Sår i munnen
Maten smaker annerledes
Vekttap
Mistet håret
Treg mage / forstoppelse
Hoven i armer og ben
"Jeg ser ikke ut som meg
 selv lengre"
Forandringer i huden
I løpet av den
siste uken:
Har du hatt noen
av de følgende
symptomene?
      Hvis JA:
Hvor ofte hadde
du symptomet?
      Hvis JA:
Hvor kraftig var
symptomet, det
meste av tiden?
     Hvis JA:
Hvor mye plaget
eller bekymret
symptomet deg?
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
Svæ
rt  
kraftig 
Kraftig 
Moderat 
Svakt 
Nesten  
hele tiden 
Ofte 
Av og til 
Sjelden 
H
ar ikke hatt sym
ptom
et 
Hvis du har hatt noen andre symptomer i løpet av den siste uken,
vennligst skriv de opp nedenfor, og angi hvor mye det
plaget eller bekymret deg.
Annet:
Annet:
Annet:
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
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1.    Gjennom livet har de fleste av oss hatt smerter (som lett hodepine, forstuelser eller tannpine).
        Har du i dag smerter av et annet slag enn slike dagligdagse smerter?
2.    Vil du skravere de områdene på kroppen hvor du har smerter.  Marker med et kryss der du har mest vondt.
Ikke fyll ut rutene (fylles ut av studiegruppen)
Høyre Høyre
SMERTER (BPI)
Ja Nei Hvis NEI, gå til side 10
Venstre Venstre
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mest vondt
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8.    I hvor stor grad har behandling eller medisiner lindret smertene dine de siste 24 timene?
       Vennligst sett ett kryss i den ruten med prosenttallet som viser hvor stor smertelindring
       du har fått.
7.    Hvilken behandling eller medisiner får du for å lindre smertene dine?
6.    Vennligst sett ett kryss i den ruten som best angir hvor sterke smerter du har akkurat nå.
     Reg. nr.:
3.    Vennligst sett ett kryss i den ruten som best beskriver de sterkeste smertene du har hatt
        i løpet av de siste 24 timer.
  Ingen
smerter
Verst tenkelige
    smerter
4.    Vennligst sett ett kryss i den ruten som best beskriver de svakeste smertene du har hatt
        i løpet av de siste 24 timer.
5.    Vennligst sett ett kryss i den ruten som best angir hvor sterke smerter du har i gjennomsnitt.
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Sett ett kryss i den ruten som for de siste 24 timene best beskriver hvor mye smertene har virket inn på:
     Reg. nr.:
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SNU ARKET!
Fullstendig
 påvirket
 9.   Daglig aktivitet 
   Ikke
påvirket
10.   Humør
11.   Evne til å gå
12.   Vanlig arbeid (gjelder både arbeid utenfor hjemmet og husarbeid)
13.   Forhold til andre mennesker
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14.   Søvn
15.   Livsglede
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SPØRRESKJEMA OM HELSE (SF-12)
     Reg. nr.:
INTRODUKSJON:  Dette spørreskjemaet handler om hvordan du ser på din egen
helse.  Disse opplysningene vil hjelpe oss til å få vite hvordan du har det og
hvordan du er i stand til å utføre dine daglige gjøremål.
Hvert spørsmål skal besvares ved å sette ett kryss (X) i den ruten som passer best
for deg.  Hvis du er usikker på hva du vil svare, vennligst svar så godt du kan.
1.   Stort sett vil du si at din helse er:
Utmerket Meget god God Nokså god Dårlig
De neste spørsmålene handler om aktiviteter som du kanskje utfører i løpet av en vanlig uke.  Er din helse
slik at den begrenser deg i utførelsen av disse aktivitetene nå?  Hvis ja, hvor mye?
2.   Moderate aktiviteter som å
      flytte et bord, støvsuge, gå en
      tur eller drive med hagearbeid
3.   Gå opp trappen flere etasjer
Ja, begrenser
   meg mye
Ja, begrenser
    meg litt
Nei, begrenser
meg ikke i det
    hele tatt
I løpet av den siste uken, har du hatt noen av de følgende problemer i ditt arbeid eller i andre av dine daglige
gjøremål på grunn av din fysiske helse?
4.  Du har utrettet mindre enn du
     hadde ønsket
5.  Du har vært hindret i å utføre
     visse typer arbeid eller gjøremål
Ja Nei
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Draft
I løpet av de siste 4 ukene, har du hatt noen av de følgende problemer i ditt arbeid eller andre av dine daglige
gjøremål på grunn av følelsesmessige problemer (som for eksempel å være deprimert eller engstelig)?
6.   Du har utrettet mindre enn du
      hadde ønsket
7.   Du har utført arbeidet eller andre
      gjøremål mindre grundig enn vanlig
Ja Nei
     Reg. nr.:
8.   I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige
      arbeid (gjelder både arbeid utenfor hjemmet og husarbeid)?
Ikke i det hele tatt Litt En del Mye Svært mye
De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det de siste 4 ukene.
For hvert spørsmål, vennligst velg det svaralternativet som best beskriver hvordan du har hatt det.
Hvor ofte i løpet av de siste 4 ukene har du:
9.   Følt deg rolig og
      harmonisk
10. Hatt mye overskudd
11. Følt deg nedenfor
      og trist
Hele           Nesten        Mye av        En del av       Litt av      Ikke i det
tiden        hele tiden       tiden             tiden           tiden        hele tatt
12. I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller
      følelsesmessige problemer påvirket din sosiale omgang (som det å besøke
      venner, slektinger osv.)?
Hele tiden Nesten hele tiden En del av tiden Litt av tiden Ikke i det hele tatt
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SØVNPROBLEMER (GSDS)
Tenk tilbake på den siste uken.  Hvor mange dager har du:  (sett ett kryss i den aktuelle ruten)
1.    Hatt problemer med å sovne
2.    Våknet i løpet av søvnperioden
3.    Våknet for tidlig og fikk ikke til å sovne igjen
4.    Følt deg uthvilt når du våkner på slutten av en
        søvnperiode
5.    Sovet dårlig
6.    Følt deg søvnig i løpet av dagen
7.    Kjempet for å holde deg våken gjennom dagen
8.   Følt deg irritabel i løpet av dagen
9.    Følt deg trøtt eller utmattet i løpet av dagen
10.  Følt deg tilfreds med søvnkvaliteten
11.  Følt deg våken og energisk gjennom dagen
12.  Fått for mye søvn
13.  Fått for lite søvn
14.  Tatt en blund til planlagt tid
15.  Sovnet uten at det var planlagt
16.  Drukket alkohol for å få til å sovne
17.  Brukt tobakk for å få til å sovne
18.  Brukt andre stimuli for å sovne (f.eks: avslapping,
         musikk, lesing)
19.  Brukt naturmedisinske midler for å sovne
20.  Brukt reseptbelagt sovemedisin for å få til å sovne
21.  Brukt Paracet eller annet smertestillende for å sove
Aldri
Hver
 dag
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DEPRESJON (CES-D)
Vennligst sett ett kryss i den ruten som markerer hvor ofte du har følt det slik
i løpet av den siste uken.
Aldri eller
  nesten
   aldri
(Mindre enn
1 dag i uken)
Litt av
  tiden
(1-2 dager
   i uken)
En del
av tiden
(3-4 dager
   i uken)
Hele eller
  nesten
hele tiden
(5-7 dager
      i uken)
1.    Jeg var plaget av ting som vanligvis ikke
         plager meg
2.    Jeg hadde dårlig appetitt
3.    Jeg var nedstemt og kunne ikke riste det av
         meg, til tross for støtte fra familie og venner
4.    Jeg følte meg like mye verdt som andre
5.    Jeg hadde problemer med å konsentrere
         meg om det jeg holdt på med
6.    Jeg følte meg deprimert
7.    Jeg følte at alt var et ork
8.   Jeg så lyst på framtiden
9.    Jeg tenkte at livet mitt hadde vært mislykket
10.  Jeg følte meg engstelig
11.  Jeg sov urolig
12.  Jeg følte meg lykkelig
13.  Jeg var mer taus enn vanlig
14.  Jeg følte meg ensom
15.  Folk var uvennlige
16.  Jeg satte pris på livet
17.  Jeg gråt
18.  Jeg følte meg trist
19.  Jeg følte at folk mislikte meg
20.  Jeg var initiativløs
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TRETTHET (LFS)
Vi ønsker å vite mer om energinivået ditt.
Nedenfor er det 18 utsagn vi ber deg svare på.
INSTRUKSJONER:  For hvert utsagn nedenfor -
Sett ett kryss i den ruten som best indikerer hvordan du føler deg akkurat nå.
 Svært
sliten
1.
Ikke sliten
i det hele
     tatt
Svært
  trøtt
2.
Ikke trøtt
i det hele
    tatt
Svært
 døsig
3.
Ikke døsig
i det hele
    tatt
  Svært
utmattet
4.
Ikke utmattet
   i det hele
       tatt
Svært
 utslitt
5.
Ikke utslitt
 i det hele
     tatt
  Svært
energisk
6.
Ikke energisk
   i det hele
       tatt
Svært
  aktiv
7.
Ikke aktiv
i det hele
     tatt
Svært
sprek
8.
Ikke sprek
i det hele
    tatt
  Svært
effektiv
9.
Ikke effektiv
  i det hele
      tatt
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Jeg har absolutt
 ikke noe behov
 for å legge meg
      nedpå
     Reg. nr.:
Svært
  livlig
10.
Ikke livlig
i det hele
    tatt
 Svært
utkjørt
11.
Ikke utkjørt
  i det hele
      tatt
 Svært
utslått
12.
Ikke utslått
 i det hele
     tatt
13.
Å holde øynene
  åpne er ikke
 anstrengende
 i det hele tatt
14.
     Å bevege
kroppen er ikke
 anstrengende
 i det hele tatt
15.
Å konsentrere
  seg er ikke
anstrengende
i det hele tatt
16.
    Å holde i gang
    en samtale er
ikke anstrengende
   i det hele tatt
17.
18.
Jeg har absolutt
 ikke noe behov
    for å lukke
      øynene
Jeg har et veldig
sterkt behov for
   å legge meg
        nedpå
Å holde øynene
 åpne er veldig
 anstrengende
     Å bevege
   kroppen er
       veldig
  anstrengende
 Å konsentrere
 seg er veldig
 anstrengende
  Å holde i gang
  en samtale er
        veldig
    anstrengende
Jeg har et veldig
    sterkt behov
     for å lukke
        øynene
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LIVSKVALITETS SPØRRESKJEMA - KREFT (MQOLS-CA)
Nedenfor følger noen spørsmål om din sykdom og din livskvalitet.  Vær vennlig
å sette ett kryss i den ruten du synes passer best for å beskrive din situasjon.
Svært
   god
helse
1.   Hvordan er din nåværende helsetilstand? 
Ekstremt
  dårlig
  helse
Tilpasningen
  er veldig
        lett
2.   Hvor lett eller vanskelig er det for deg å tilpasse deg din sykdom og behandling? 
Tilpasningen
er ikke lett i
det hele tatt
 Mye
glede
3.   Hvor stor glede har du av livet?
Ingen
glede
Veldig stor
økonomisk
   trygghet
4.   Føler du økonomisk trygghet? 
        Ingen
    økonomisk
  trygghet i det
     hele tatt
  Svært
plagsomt
5.   Hvis du har smerter, hvor plagsomt er det?
 0           1           2          3           4           5          6           7          8           9         10
Ikke plagsomt
i det hele tatt,
   eller ingen
    smerter
Veldig
nyttig
6.   Hvor nyttig føler du deg? 
Ikke nyttig
 i det hele
     tatt
  Svært
lykkelig
7.   Hvor lykkelig føler du deg?
   Føler meg
 ikke lykkelig
i det hele tatt
      Svært
tilfredsstillende
8.   Hvor tilfredsstillende er livet ditt? 
        Ikke
tilfredsstillende
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  Akkurat
passe med
kjærlighet
9.   Får du nok kjærlighet fra familie og venner?
   Ikke nok
eller for mye
  kjærlighet
  Meget stor
  påvirkning på
mine personlige
    relasjoner
10.  Påvirker din sykdom eller behandling dine personlige relasjoner?
  Påvirker ikke
mine personlige
 relasjoner i det
     hele tatt
Bekymret
   hele
   tiden
    Aldri
bekymret
I full stand til
 å gjøre ting
   jeg liker å
        gjøre
12.  I hvor stor grad er du i stand til å gjøre ting du liker å gjøre, som f.eks, å se på TV,
       lese, gjøre hagearbeid, høre på musikk, gå turer, spille tennis, spille kort, osv.?
Absolutt ikke i
stand til å
gjøre ting jeg
 liker å gjøre
    Utmerket
konsentrasjons-
        evne
13.  Hvordan er din nåværende konsentrasjonsevne?
  Veldig dårlig
konsentrasjons-
        evne
 Mye
krefter
14.  Hvor mye krefter har du?
Ingen krefter i
det hele tatt
 Jeg blir
svært fort
   sliten
15.  Blir du fort sliten?
Jeg blir ikke
  fort sliten
Jeg får dekket
   mitt behov
     for søvn
16.  Får du dekket ditt behov for søvn?
Jeg får ikke
  nok søvn
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11.  Er du bekymret (redd eller engstelig) for utfallet av sykdommen din?
SNU ARKET!
Draft
     Reg. nr.:
   Jeg er
fullstendig
selvhjulpen
18.  Klarer du å ivareta dine personlige behov (kle på deg, gre håret, gå på toalettet,
       spise, dusje, bade)?
    Jeg kan
   ikke gjøre
noenting selv
Svært mye
 smerter
19.  Hvor mye smerter har du?
 Ikke smerter
i det hele tatt
Utmerket
appetitt
20.  Hvordan er appetitten din?
  Ingen
appetitt
    Veldig bra
  tarmfunksjon
  (regelmessig,
ingen diaré eller
  forstoppelse)
21.  Hvordan er tarmfunksjonen din?
    Det har aldri
      fungert så
  dårlig før (enten
    for mye diaré,
eller forstoppelse)
  Spiser
passe mye
22.  Spiser du nok i forhold til ditt behov?
  Spiser ikke
riktig mengde
(for mye eller
     for lite)
 Veldig
bekymret
23.  Er du bekymret for vekten din?
      Ikke
bekymret for
vekten i det
   hele tatt
Konstant
   kvalm
24.  Er du plaget av kvalme?
Aldri kvalm
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Svært god
livskvalitet
17.  Hvor god er din livskvalitet?
Svært dårlig
 livskvalitet
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     Reg. nr.:
Maten smaker
      veldig
  annerledes
26.  Smaker maten annerledes?
   Maten
  smaker
som vanlig
   Kommer
  meg rundt
på egenhånd
27.  Klarer du å komme deg rundt i den grad du ønsker (gå rundt i rommet, eller
       hjemmet ditt, komme deg ut, handle, kjøre bil eller ta offentlig transport, osv.)?
Fullstendig
 bundet til
  sengen
Meget fornøyd
    med mitt
    utseende
28.  Hvor fornøyd er du med utseendet ditt?
       Meget
misfornøyd med
 mitt utseende
 Veldig
bekymret
29.  Er du bekymret for noe du ikke har fullført (privat eller på jobb)?
         Ikke
    bekymret
i det hele tatt
Ivaretar dette
ansvaret godt
30.  Føler du at du ivaretar ditt ansvar overfor andre (familie, nærmiljøet, kirke, el.)?
 Ivaretar
ikke dette
 ansvaret
   Livet er
     svært
 meningsfylt
31.  Har livet mening for deg?
Livet har
   ingen
  mening
Riktig mengde
   emosjonell
       støtte
32.  Får du tilstrekkelig emosjonell støtte fra familie og venner?
Ikke nok eller
     for mye
  emosjonell
      støtte
Jeg bidrar til
å gjøre andre
 veldig glad
33.  Føler du at du bidrar til å gjøre andre glad (familie og venner)?
 Jeg bidrar
  ikke til å
gjøre andre
      glad
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Kaster opp
hele tiden
25.  Kaster du opp?
 Kaster
aldri opp
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Vennligst legg ferdig utfylt spørreskjema i 
svarkonvolutten. Porto er betalt. 
Tusen takk for hjelpen! 
Senter for pasientmedvirkning og sykepleieforskning 
Besøksadresse: Forskningsveien 2b, Oslo 
Postadresse: Rikshospitalet HF, 0027 Oslo 
Sentralbord: 23 07 00 00  
Direktelinje: 23 07 54 64 
Epost: kristin.hofso@rr- research.no
tone.rustoen@rr- research.no
